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1. Introduction 
 
1.1 Gene Therapy 
 
Gene therapy is defined as the transfer of nucleic acids (DNA or RNA) to patients’ cells for the 
treatment of human diseases. It can be divided into two categories: “in vivo” and “ex vivo” gene 
therapy. In the first approach, the therapeutic gene is directly introduced into the patients’ body 
(e.g. muscle, liver), while in the second approach, the patients’ cells are isolated from the body, 
genetically modified in the laboratory and reintroduced into the patients’ body.  
 
Depending on the type of disease, gene therapy can be achieved either by addition of a functional 
cDNA copy as a substitute for the mutated gene to restore the normal genetic function (gene 
addition) or by using RNA interference to knock down the dominant negative and toxic gain-of-
function gene products (gene silencing). Recently, gene targeting therapy has been brought to the 
forefront as a potential therapy approach for many monogenetic diseases, which aims at 
correcting the defective endogenous counterpart through homologous recombination based DNA 
double strand break repair (DSBR). Besides the correction of mutations that cause diseases, this 
genome-editing technology also enables the scientist to add therapeutic genes to the specific site 
in the genome and to precisely remove the mutated genome sequence. These innovative 
approaches have generated great enthusiasm and successfully moved from bench to bedside 
(Kaufmann, Buning et al. 2013). 
 
1.1.1 Gene therapy in the past 
 
In 1990, the first “ex vivo” gene therapy was performed by Dr. William French Anderson on two 
children with adenosine deaminase deficiency (ADA-SCID), a monogenetic disease leading to 
severe combined immunodeficiency. The T cells were isolated from these two patients and 
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transduced with an ADA-containing retroviral vector to express normal ADA gene. Both patients 
have shown increased T lymphocyte counts in the blood as well as ADA enzyme activity in one 
patient after the treatment (Blaese, Culver et al. 1995). Although the effects were temporary and 
many components remain to be perfected, it sets a new milestone in the development of gene 
therapy. 
 
With this notable success, more promising results have been obtained from the clinical trials 
suffering from Leber’s congenital amaurosis (Bainbridge, Smith et al. 2008, Maguire, Simonelli 
et al. 2008), haemophilia (Lheriteau, Davidoff et al. 2015), β-thalassemia (Cavazzana-Calvo, 
Payen et al. 2010), diabetes (Elsner, Terbish et al. 2012) and Parkinson’s disease (Stoessl 2014). 
Between 1990 and 2013 more than 1900 clinical trials have been conducted with a varying 
degree of success and no major side effects reported (Kaufmann, Buning et al. 2013). 
 
In 2004, China introduced the world’s first commercial gene therapy drug (Gendicine®) into the 
market for the treatment of patient with head and neck squamous cell carcinoma (HNSCC) 
(Pearson, Jia et al. 2004, Peng 2005,Wilson 2005). Gendicine
®
 is a recombinant human serotype 
5 adenovirus genetically engineered to express the human p53 gene. The p53 gene is one of the 
most widely studied tumor suppressor genes, which plays a crucial role in preventing cancer 
formation. Because of its important role in preventing genome mutation and maintaining genome 
stability, the p53 gene has been described as "the guardian of the genome". After intratumoral 
injection of Gendicine
®
, the adenoviral particle delivers the therapeutic p53 gene to the 
cytoplasm and nucleus for the expression without integrating it in the host cells’ chromosomes. In 
clinical trials and application, infiltration of many lymphocytes and inhibition of VEGF activity 
in biopsies of tumor lesions were observed. The combination of Gendicine
®
 with radiotherapy 
has shown significant synergistic effects in Phase II/III clinical trials, with 64% complete 
regression and 29% partial regression (Peng 2005). The only side effect of Gendicine
®
 is self-
limited fever after more than five years clinical observation (Pearson, Jia et al. 2004). Gendicine
®
 
represents a remarkable medical achievement, and it opened the door for a gene therapy market 
in the near future. 
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In Europe, the first commercial gene therapeutic product Glybera
®
 was approved by the 
European Commission at the end of 2012 (Miller 2012). Glybera
®
 is an adeno-associated viral 
vector engineered to express lipoprotein lipase (LPL) for the treatment of familial lipoprotein 
lipase deficiency (LPLD). Familial LPLD represents a rare autosomal recessive disorder usually 
present in childhood characterized by severe hypertriglyceridemia with abdominal pain, recurrent 
acute pancreatitis, eruptive cutaneous xanthomata, hepatosplenomegaly, and other complications 
(Brunzell 1993). Familial LPLD is caused by extremely low or absent activity of LPL, the key 
enzyme responsible for hydrolysis of triglyceride-rich lipoproteins (Goldberg 1996). LPL 
interacts with circulating chylomicrons in the vascular lumen and converts triglyceride into free 
fatty acids (Bryant, Christopher et al. 2013). Without LPL, triglyceride cannot be depleted, 
leading to the accumulation of triglyceride-rich lipoproteins in the plasma (Goldberg 1996). After 
injection of Glybera
®
 into the leg muscle, patients showed a long-term reduction of triglyceride 
levels (Gaudet, Methot et al. 2012). Although the clinical results were based on a small number 
of patients, the marketing authorization for Glybera
®
 represents a landmark in the gene and cell 
therapy field. 
 
Since the successes in the gene therapy area are based on the addition of a therapeutic gene for 
the treatment of loss of function genetic diseases, the application is very limited by other types of 
diseases like autosomal recessive and gain-of-function diseases. Therefore, great efforts are made 
in the genome editing field to cut and repair the endogens precisely though homologous 
recombination, which can be applied to any kind of monogenic diseases. 
 
1.1.2 Gene transfer 
 
Despite clinical success, the understanding of various gene transfer tools and molecular 
mechanisms has resulted in the development of gene therapy approaches with improved safety 
and therapeutic efficacy. Over the past years, genetically engineered viral and non-viral vectors 
are widely used for the delivery of therapeutic genes to the specific human cells. 
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Viral vectors, such as adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, 
and retroviral vectors, are the most common viral delivery vectors, which provide efficient gene 
transduction and effective gene expression in over 68% of gene therapy clinical trials (Santiago-
Ortiz and Schaffer 2016). 
 
AAV vectors in particular are widely used for many in vivo gene transfer applications to both 
dividing and non-dividing cell populations with low host immune response, high transferring 
ability, long-term gene expression, and low toxicity (Kotterman and Schaffer 2014). As a result 
of these properties, AAV is becoming a promising approach to treat a variety of diseases and 
cancers, including hemophilia B, LPLD, Alzheimer’s disease, Parkinson’s disease, inherited 
retinal dystrophies (IRD), and liver cancer (Luo, Luo et al. 2015). 
 
AAV is a linear single-stranded DNA (ssDNA) parvovirus. The wild-type AAV genome, which 
is about 4.7 kb long, comprises two open reading frames encoding Rep and Cap protein flanked 
by two hairpin palindromic repeat sequences termed inverted terminal repeats (ITRs) (Santiago-
Ortiz and Schaffer 2016). The Rep gene codes for non-structural proteins expressed via 
alternative promoters, which are involved in viral replication, transcription, packaging, and 
genomic integration. The Cap gene encodes the structural proteins VP1, VP2, VP3 that assemble 
to form the viral capsid (Deyle and Russell 2009). In the absence of a helper virus, the AAV 
genomes can establish latency and persist in the host as episomes or in some cases integrate into 
the host genome on the long arm of chromosome 19 in a site-specific manner. In the presence of 
a helper virus such as adenovirus or herpesvirus, the AAV can enter its replication cycle and 
undergoes productive infection (Deyle and Russell 2009). Infection is initiated by low-affinity 
binding to glycans followed by cell surface receptor-mediated endocytosis. Endosomal escape, 
endosomal trafficking, and viral capsid uncoating occurs and the single stranded DNA undergoes 
double strand synthesis, which is capable of transcription and gene expression(Lisowski, Tay et 
al. 2015). 
 
Recombinant adeno-associated viruses (rAAVs) are generated by replacing the viral ORFs with 
transgene expression cassettes containing the gene of interest. Rep and Cap genes, as well as 
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helper genes required for AAV replication are provided in trans (Fig. 1). Either single-stranded 
DNA genomes of 4.7 kb or self-complementary DNA genomes of approximately 2.2 kb can be 
packed into AAV vectors (Gray and Zolotukhin 2011). For large therapeutic genes (> 4.7 kb), 
different strategies have been developed to expand the packaging capacity imposed by the viral 
genome. These include minimizing the expression elements in the expression cassette, truncating 
the gene itself, or using trans-splicing and overlapping vectors based on post-transduction 
concatemerization of the transgene (Chira, Jackson et al. 2015).  
 
 
 
 
Fig. 1: Generation of recombinant AAV vectors. Recombinant AAV vectors are generated by replacing the 
viral ORFs with transgene expression cassettes containing the promoter, therapeutic gene and pA sequence. At 
the left side of the picture is the hexagonal three-dimensional structure of the viral capsid and electron 
microscopy image of the individual 21nm large virus (Stieger and Lorenz 2008). 
 
However, their applications are limited to the inherent proprieties of the target gene. A hybrid 
dual vector system has been developed as a potential solution to this problem by inserting a 
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highly recombinogenic alkaline phosphatase (AP) sequence in the trans-splicing vector, which 
allows the AP sequence-mediated transgene reconstitution through homologous recombination 
(Ghosh, Yue et al. 2008). These recent advances may offer a strong potential for large gene 
reconstitution, however, further understanding of vector-host-interaction and endogenous 
mechanisms are required for achieving successful therapeutic application. 
 
Another important type of vector for gene therapy is derived from lentiviruses (LV), which have 
been used particularly for the treatment of central nervous system disorders. Lentiviruses are able 
to transduce both dividing and non-dividing cells with high transduction efficacy, long-term 
stable expression of the transgene, and low immunogenicity (Chira, Jackson et al. 2015). 
Typically, vector particles are produced by cotransfection of the lentiviral vector plasmid and 
three helper constructs (pMDL, pRev and pVSVG) in the packaging cell. The vector plasmid 
contains the vector genome and the transgene, while the helper constructs encode the proteins 
that are essential for the viral life cycle (Tiscornia, Singer et al. 2006). Compared to AAVs, LV 
can accommodate larger transgenes up to 10 kb, which broadens the applicability of LVs for gene 
therapy application (Matrai, Chuah et al. 2010) (Fig. 2).  
 
Upon transduction of the target cells, the virion enters the host cells by binding to the cell surface 
receptors and co-receptors, leading to endocytosis or direct fusion with the cell membrane. After 
entry, the internal core is released and the RNA transgene is reverse transcribed to the cDNA. 
The viral core containing the cDNA is then transported to the nucleus and the cDNA is integrated 
into the host cell chromosome, resulting in persistent expression of the transgene (Tang, Kuhen et 
al. 1999). However, activation of proto-oncogenes at the site of genomic integration suggests the 
carcinogenic effect of LVs in the host genome. To overcome this limitation, self-inactivating 
(SIN) vectors and integration-deficient lentiviral vectors (IDLV) have been developed by deleting 
the U3 region of the 3’LTR and mutational inactivation of the integrase protein, respectively 
(Matrai, Chuah et al. 2010). These recent achievements highlight the improved safety of LVs 
with important implication for further clinical purposes. 
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Fig. 2: Recombinant lentivirus vectors. The viral ORFs of the wild type Lentiviruses are replaced by the 
expression cassette of the therapeutic gene, which is maximal 7 kb long (Stieger and Lorenz 2014). LTR: Long 
terminal repeat; SIN: Self inactivating LTR; RRE: Rev Response Element; Ψ: Pack sequence psi.  
 
Despite accumulating data on improved viral vectors, non-viral vectors, such as naked plasmids, 
nanoparticles, cationic liposomes and cationic polymers have also shown their advantages in the 
gene therapy field. In contrast to viral-vectors, non-viral vectors are typically easy to synthesize, 
and the immunogenicity is lower. Non-viral vectors are also capable of delivering large 
therapeutic genes and synthetic expression cassettes like siRNA. The limitations of non-viral 
vectors are related to extracellular stability, internalization, intracellular trafficking, nuclear entry, 
and the sustainability of expression of the transgene. Several strategies have been developed to 
overcome these limitations by using carrier molecules, targeting ligands, endosomal disruptive 
agents, and nuclear localization signal (Ramamoorth and Narvekar 2015). 
 
Besides these recent improvements in gene delivery vectors and a large amount of clinical 
successful events, the development of programmable nucleases and the understanding of nuclease 
functions opened the new era of genome editing field. 
 
1.2 Highly specific nucleases 
 
In recent years, several programmable nucleases like meganucleases, zinc-finger nucleases 
(ZNFs), transcription activator-like effector nucleases (TALENs) and RNA-guided 
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endonucleases (RGNs) have become powerful tools for precise and efficient genome engineering. 
These engineered nucleases can create site-specific DNA double-strand breaks, and the induced 
double-strand breaks can be repaired through different DNA repair pathways including 
homologous recombination, non-homologous end joining, and microhomology-mediated end 
joining (Fig. 3). To induce site-specific DNA DSB in the human genome of 3 x 10
9
bp, the 
recognition site of the nucleases should be 16-18 bp in length (Chandrasegaran and Carroll 2016).  
 
To date, ZNFs and TALENs have been used in more than 40 different organisms and cell types, 
which have shown their successes in genome editing area (Chandrasegaran and Carroll 2016). A 
more recent genome editing tool is the CRISPR-Cas9 system, which has been described as an 
adaptive defense mechanism in bacteria and archaea. In the past three years, CRISPR-Cas 
systems have been used in a wide range of organisms, including Drosophila melanogaster (Gratz, 
Cummings et al. 2013), Caenorhabditis elegans (Friedland, Tzur et al. 2013), Saccharomyces 
cerevisiae (DiCarlo, Norville et al. 2013), zebrafish (Chang, Sun et al. 2013), mice (Wang, Yang 
et al. 2013), rat (Li, Qiu et al. 2013, Li, Teng et al. 2013), plants (Jiang, Zhou et al. 2013), 
monkeys (Niu, Shen et al. 2014) and human embryos (Kang, He et al. 2016). 
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Fig. 3: Description of the different programmable nucleases and three major repair pathways. (A) 
Schematic drawing of ZNF, TALEN, and CRISPR-Cas. The DNA binding domains are represented in 
turquoise, the cleavage domains are in yellow. (B) Three major repair pathways occur after the introduction of 
the DNA double strand breaks, including NHEJ, HDR, and MMEJ (Yanik, Muller et al. 2016).  
 
1.2.1 Zinc finger nucleases 
 
ZNFs were the first artificial targetable nucleases, which can be customized to cleave any given 
sequence in the genome (Kim and Berg 1996). ZFNs consist of a programmable DNA-binding 
domain of zinc finger proteins (ZFPs) and a non-specific DNA cleavage domain of type II 
restriction endonuclease FokI (Kim, Cha et al. 1996). Because the binding domain of the ZFPs 
can be easily manipulated, they have become powerful tools for genome engineering and have 
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been used to site-specifically modify the genomes in various organisms, including frogs, insects, 
fish, plants, mice, rats and cultured human cells (Wu, Kandavelou et al. 2007). Furthermore, 
ZFNs are the only genome editing tools that have been tested in clinical trials for the treatment of 
Hemophilia B, Mucopolysaccharidosis I and HIV infections (Yanik, Muller et al. 2016). 
 
 
 
 
Fig. 4: Schematic representation of DNA binding by zinc finger protein. Each zinc finger usually 
recognizes 3 base pairs DNA through four contact amino acids at positions 1, 2, 3, 6 of each helix 
(shown in purple) (Pingoud, Wilson et al. 2014). 
 
The DNA-binding domain of ZFNs contains 3 to 6 Cys2-His2 zinc fingers. Each zinc finger (ZF) 
is composed of approximately 30 amino acid residues in a unique ββα configuration, which is 
stabilized by a zinc atom (Pavletich and Pabo 1991). An individual zinc finger usually recognizes 
3 base pair DNA sequences by inserting an α-helix into the major groove of the DNA double 
helix (Pavletich and Pabo 1991) (Fig. 4). The binding specificity of the ZFP has a direct 
influence on the cleavage specificity, which can be achieved by adding more ZF motifs to the 
ZFPs, but the recognition of DNA by individual ZFs appears to be dependent of the neighboring 
modules (Urnov, Miller et al. 2005, Urnov, Rebar et al. 2010). To construct multi-finger arrays 
and to improve the binding specificity, different strategies have been developed, including OPEN 
(Oligomerized Pool ENgineering) and CoDA (Context-Dependent Assembly) (Maeder, 
Thibodeau-Beganny et al. 2008, Sander, Dahlborg et al. 2011). 
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To produce a DSB, the nuclease domain of the FokI endonuclease must be dimerized for the 
formation of the active center (Bitinaite, Wah et al. 1998, Wah, Bitinaite et al. 1998). Therefore, a 
pair of ZFNs binding to adjacent, oppositely oriented sites on the DNA is required for the 
induction of the DSB (Smith, Bibikova et al. 2000). Paired binding sites of ZFNs doubled the size 
of the target sequence recognition and increased the specificity of ZFNs. Normally, a pair of 3- or 
4- finger ZFN monomers has an 18- or 24- bp recognition site in a tail-to tail orientation, which is 
long enough to specify a unique genomic sequence in mammals and plants (Wu, Kandavelou et 
al. 2007). However, due to the unspecific DNA cleavage domain and unexpected binding to 
nonspecific DNA sequences, significant off-target cleavage effects have been observed besides 
the on-target cleavage, indicating that still great efforts should be made to improve the specificity 
of the ZFNs (Gabriel, Lombardo et al. 2011, Pattanayak, Ramirez et al. 2011).  
 
1.2.2 TALENs (transcription activator-like effector nucleases) 
 
TALENs (transcription activator-like effector nucleases) are another type of highly specific 
nucleases, which can be designed to cleave any given DNA sequences for targeted modification 
of endogenous genes. The general modular structure of TALENs is similar to that of ZFNs, 
which is based on a specific DNA binding domain of bacterial TALEs fused to the unspecific 
DNA cleavage domain.  
 
The DNA binding domains TALEs (transcription activator-like effectors) are transcriptional 
activators that are derived from the bacterial plant pathogen Xanthomonas (Bonas, Stall et al. 
1989). TALEs contain N- and C- termini for localization and a central repeat domain for specific 
DNA binding (Boch and Bonas 2010). The central repeat domain of TALE proteins is composed 
of 5 to over 30 tandem repeats with an average of 17.5 (Wei, Liu et al. 2013). Each repeat 
contains 33-35 amino acid residues and recognizes one base pair in the target DNA via unique 
repeat variable di-residues (RVD) at position 12 and 13 (amino acid residue NI recognizes A, HD 
recognizes C, NG or HG recognizes T, and NN recognizes G or A), which determines the 
nucleotide binding specificity of each repeat (Deng, Yan et al. 2012, Mak, Bradley et al. 2012) 
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(Fig. 5). Since there is no considerable context-dependent interaction between the neighboring 
repeats, TALENs have much more advantages compared to ZFNs (Yanik, Muller et al. 2016). 
 
 
 
 
Fig. 5: Schematic representation of DNA binding by TAL effector.The DNA binding domain of 
TALEs consists of a series of repeats and each repeat recognizes one base pair in the target DNA via 
repeat variable di-residues (RVD) at position 12 and 13.  The RVD (HD) is shown in red (Pingoud, 
Wilson et al. 2014). 
 
By fusing the nuclease cleavage domain such as FokI and PvuII with an artificial TALE binding 
domain, TALENs have been used in a wide range of model organisms and cell types, including 
flies, frogs, fish, rats, mice, human somatic cells, and human cells (Miller, Tan et al. 2011, Wei, 
Liu et al. 2013, Yanik, Muller et al. 2016). In 2015, the first-in-man application of TALEN 
engineered universal CAR19 T cells took place and will now be tested in clinical trials (Yanik, 
Muller et al. 2016). 
 
1.2.3 CRISPR-Cas system 
 
Recently, the development of CRISPR-Cas (clustered regularly interspaced short palindromic 
repeats-CRISPR-associated proteins) systems is revolutionizing the field of genome editing, 
enabling the scientists to manipulate the genomes for therapeutic application with relative ease. 
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The CRISPR-Cas systems are prokaryotic immune systems, which provide adaptive immunity 
against invading phages and foreign nucleic acids. CRISPR-Cas systems are present in roughly 
half of all sequenced bacterial genomes and almost all of sequenced archaeal genomes 
(Barrangou, Fremaux et al. 2007, Wright, Nunez et al. 2016).  
 
In these species, CRISPR arrays contain a series of short, palindromic DNA repeats ranging from 
21 to 48 bp, interspaced by 26 to 72 bp variable spacer sequences derived from invading 
pathogens (Bondy-Denomy and Davidson 2014). The CRISPR array is usually located adjacent 
to a cluster of CRISPR-associated (cas) genes and preceded by an AT-rich leader sequence 
(Amitai and Sorek 2016). Depending on the Cas genes and the proteins they encode, three major 
types of CRISPR-Cas systems have been identified, namely Type I, Type II and Type III, and 
these can be further divided into several subtypes, given their structural and functional diversity 
(Amitai and Sorek 2016). The key protein of Type I systems is Cas3, while the signature protein 
of Type III systems is Cas10. The most widely used CRISPR systems are the Type II CRISPR-
Cas9 systems from Streptococcus pyogenes, which are signified by Cas9 protein (Wright, Nunez 
et al. 2016). 
 
Overall, CRISPR immunity can be divided into three stages: adaption, CRISPR RNA (crRNA) 
biogenesis, and interference (van der Oost, Westra et al. 2014, Makarova, Wolf et al. 2015). In 
the adaption stage, foreign DNA is identified and integrated into the CRISPR array as a new 
spacer. During the crRNA biogenesis stage, the CRISPR array is transcribed and processed into 
small crRNAs that each contains a single spacer flanked by CRISPR repeat sequences. These 
mature crRNAs are subsequently combined with Cas proteins for the formation of the active Cas-
crRNA complex. In the interference stage, the Cas-crRNA complex recognizes foreign nucleic 
acid sequence complementarity to the crRNA sequence, which leads to the successful cleavage 
and degradation of the DNA and RNA molecules (Fig. 6). 
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Fig. 6: Three stages of CRISPR immunity: adaption, crRNA biogenesis, and interference. During the 
adaption stage, foreign DNA is identified and integrated into the CRISPR array as a new spacer. In the 
crRNA biogenesis stage, the CRISPR array is transcribed and processed into small crRNA, which combines 
with Cas protein and forms the active Cas-crRNA complex. The Cas-crRNA complex recognizes and 
cleaves the foreign DNA 3 bp upstream of the PAM sequence. 
 
 
The engineered Type II CRISPR-Cas9 system consists of the Cas9 DNA endonuclease and a 
chimeric single guide RNA (gRNA). The gRNA contains a 20 nt programmable CRISPR RNA 
(crRNA) and a trans-activating crRNA (tracrRNA), which forms a double-stranded RNA 
structure and binds to Cas9that form a complex for cleavage (Jinek, Chylinski et al. 2012, Hsu, 
Lander et al. 2014). Next to the target sequence, a 2-5 nucleotide motif is required for the target 
recognition; named protospacer adjacent motif (PAM) that usually consists of a 5’-NGG-3’ 
trinucleotide, in which N can be any nucleotide (Horvath and Barrangou 2010). Upon recognition 
Adaption 
crRNA biogenesis 
Interference 
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of gRNA and target DNA sequence, the Cas9-gRNA-target DNA ternary complex initiates the 
subsequent cleavage of the target strand by the HNH nuclease domain, and of the non-target 
strand by the RuvC domain (Fig. 7) (Amitai and Sorek 2016). 
 
 
 
 
 
Fig. 7: CRISPR-Cas9 mediated DNA double strand break. (A and B) Crystal structure of Cas9-
sgRNA-dsDNA ternary complex. The target DNA strand and nontarget strand are colored dark blue 
and purple, respectively. sgRNA is shown in orange (Amitai and Sorek 2016) (C) Upon the 
recognition of 20 bp target DNA next to the PAM sequence, DNA double strand break is mediated by 
the two activate centers of the Cas9 protein, RuvC and HNH. TS, target strand; NTS, nontarget strand. 
 
A B 
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Beyond the introduction of the DNA breaks, CRISPR technologies have also been used in 
different ways, such as regulating gene expression, modifying epigenomes, and dynamic imaging 
of chromatin. Specifically, the CRISPR-associated catalytically inactive dCas9 protein has been 
fused to transcription repressor or activator domains for the regulation of gene expression in 
human and yeast cells (Gilbert, Larson et al. 2013, Larson, Gilbert et al. 2013,Gilbert, Horlbeck 
et al. 2014). By using eGFP-tagged dCas9 protein and sequence-specific gRNA, dCas9 chimeras 
enable the imaging of DNA and visualization of chromatin organization and dynamics in living 
human cells (Chen, Gilbert et al. 2013). Likewise, the CRISPRainbow technique based on dCas9 
combined with fluorescence-labelled gRNA has demonstrated simultaneous imaging of up to six 
distinct chromosomal loci in living cells (Ma, Tu et al. 2016). Recently, CRISPR-Cas9-based 
acetyltransferases and demethylases enable the epigenetic regulation and provide a new tool for 
manipulating gene expression (Hilton, D'Ippolito et al. 2015, Pham, Kearns et al. 2016). 
 
 
1.3 DNA double strand break repair 
 
1.3.1 DNA damage responses (DDR) 
 
In human cells, DNA damage takes place at a rate of 10,000 to 1,000,000 molecular lesions per 
cell per day. It can be caused by exogenous agents and endogenous cellular processes, such as 
ionizing radiation (IR), ultraviolet light (UV), chemical agents, and replication errors 
(Hoeijmakers 2001, Hoeijmakers 2001). One of the most dangerous types of DNA damage is a 
double-strand break (DSB) that can result in the introduction of gene mutations, chromosome 
rearrangement, and cell death (Khanna, Lavin et al. 2001). DNA double strand breaks can also be 
induced artificially by using highly specific nucleases and through the addition of template DNA 
to trigger the desired repair outcomes. Efficient and accurate DNA repair is crucial for the 
maintenance of genomic stability and prevention of tumor formation. Designed DNA cut and 
repair can be used as a potential therapeutic approach to repair the disease causing mutations. In 
mammalian cells, DNA double-strand breaks (DSBs) can be repaired by different pathways, 
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homologous recombination (HR), classical nonhomologous end joining (c-NHEJ), 
microhomology-mediated end joining (MMEJ), and single-strand annealing (SSA) (Helleday, 
Petermann et al. 2008). In the cell division cycle, multiple cyclin-dependent kinases (CDKs) are 
periodically activated and play a central role in DNA repair pathway choices. C-NHEJ can occur 
in any phase of the cell cycle but is dominant in G0/G1 and G2, whereas HR usually takes place 
in S and G2 cell phases because it uses sister-chromatid sequences as the template for repair 
(Sancar, Lindsey-Boltz et al. 2004). 
 
In addition to these repair pathways, DNA damage response (DDR) also plays a key role in 
combating threats posed by DNA damage. It is a signal transduction pathway that enables the cell 
to detect DNA lesions, propagate DNA damage signals, and promote their repair. DDR pathway 
is mediated by the activation of ataxia-telangiectasia mutated (ATM), ataxia-telangiectasia 
RAD3-related kinase (ATR), and DNA-dependent protein kinase (DNA-PK). ATM is primarily 
activated by double-stranded DNA breaks (DSBs), whereas ATR responds to RPA-coated single-
stranded DNA (ssDNA) region.  
 
The key regulator of ATM activation is the Mre11-Rad50-Nbs1 (MRN) complex, which 
functions as a DSB sensor and is required to recruit DDR downstream proteins. DNA-PK 
promotes DSB religation and is involved in the non-homologous end joining pathway of DNA 
repair (Goldstein and Kastan 2015). Once the activated ATM and ATR kinases are at the DSB, 
they phosphorylate a number of substrates such as H2AX, NBS1, CHK1, BRCA1, p53, and 
CHK2. The phosphorylated form of H2AX (known as γH2AX), is recognized by the mediator of 
DNA damage checkpoint 1 (MDC1), which then recruits ring finger protein 8 (RNF8), an E3 
ubiquitin ligase. RNF8 promotes another E3 ligase ring finger protein 168 (RNF168) to 
ubiquitinate H2A-type histones, leading to the recruitment of the p53 binding protein 1 (53BP1) 
and receptor-associated protein 80 (RAP80) to DSB sites (Bohgaki, Bohgaki et al. 2013).  
 
After the DNA damage responses, different repair key proteins affect the decision of the repair 
pathway choices with collaboration and competition (Kass and Jasin 2010). Understanding of the 
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repair mechanisms helps us to inhibit the error-prone repair pathway and bias the repair outcomes 
toward HDR. 
 
1.3.2 Homologous recombination (HR) 
 
HR is a central pathway for accurate DNA double strand break repair (DSBR), which is 
described as an error-free repair mechanism. HR uses an undamaged homologous sequence as a 
donor template for repair and requires RAD51-mediated strand invasion. HR is initiated by 
resection of DNA ends at the DSB site. In most cases, DNA end resection in eukaryotes is a two-
step process (Mimitou and Symington 2008, Zhu, Chung et al. 2008,Ceccaldi, Rondinelli et al. 
2016). In the initial phase of the end resection, a small number of base pairs (fewer than 20 bp in 
mammalian cells, 100-200 bp in yeast) are processed by MRE11-RAD50-NBS1 (MRN) complex 
and CtBP-interacting protein (CtIP) (Zhu, Chung et al. 2008, Truong, Li et al. 2014).  
 
Following the initial DNA processing, the extension resection (which is known as 5’-3’ resection) 
is mediated by helicases and nucleases (i.e., CtIP, EXO1, DNA2, BLM, WRN) to generate a long 
stretch of 3’ single-strand DNA (ssDNA) for strand invasion (Sturzenegger, Burdova et al. 2014, 
Ceccaldi, Rondinelli et al. 2016). During this process, end resection is promoted by cyclin-
dependent kinase (CDK)-dependent phosphorylation of multiple substrates, such as DNA2, CtIP, 
and EXO1 (Yun and Hiom 2009, Chen, Niu et al. 2011,Tomimatsu, Mukherjee et al. 2014). Next, 
the resected DNA is coated by ssDNA-binding protein replication protein A (RPA) to minimize 
the formation of secondary structures. RPA is then displaced and the Rad51 is loaded onto the 
ssDNA to form a nucleoprotein filament, a step that is mediated by BRCA2 (breast cancer type 2) 
and RAD52 (Renkawitz, Lademann et al. 2014). After RAD51 formation, homology search and 
DNA strand invasion takes place leading to D loop formation between the broken DNA and the 
intact homologous donor sequence (Sancar, Lindsey-Boltz et al. 2004).  
 
More than three different pathways are proposed after the D-loop intermediate. In the classic 
double-strand break repair (DSBR) model, the 3’ end in the D loop is extended by repair 
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synthesis and the second DSB end aligns with the extended D‑loop to form a double holliday 
junction (DHJ). Crossover and non-crossover overcomes are produced by resolvases or combined 
helicase/topoisomerase, such as GEN1, MUS81-EME1 complex, and BLM-TOPOIIIα-RMI1-
RMI2 (BTR) complex (Matos and West 2014). According to the synthesis-dependent strand 
annealing (SDSA) model, the nascent strand from the D-loop anneals to the 3’ end of the broken 
chromosome and the single-stranded gaps are filled in by DNA synthesis and ligation. This type 
of repair results in non-crossover products (Rodgers and McVey 2016). In break-induced 
replication (BIR), only one end of the DSB aligns homology with the template and the D-loop is 
assembled into the replication fork (Fig. 8). Replication of the entire homologous template arm 
results in a large-scale loss-of heterozygosity (LOH) (Pardo, Gomez-Gonzalez et al. 2009). 
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Fig. 8: Homology-directed DNA repair pathway. HDR is initiated by DNA end resection at the DSB 
site, followed by the binding of RPA and Rad51. In the presence of DNA donor template, precise DNA 
repair takes place resulted in crossover or non crossover products.  
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1.3.3 Non homologous end joining (NHEJ) 
 
NHEJ has been considered as error-prone repair of DSBs, which is characterized by re-ligating of 
two broken ends independently of sequence homology. NHEJ is a predominant DNA double 
strand repair pathway, which is always associated with the introduction of small insertions and 
deletions (indels) at the break site. Non homologous end joining is initiated by the binding of the 
KU70/80 heterodimer, followed by recruitment and activation of the DNA protein kinase 
catalytic subunit (DNA-PKcs). Binding of the Ku heterodimer protects the broken ends from 
extensive resection and inhibits their degradation. DNA-PKcs undergoes autophosphorylation 
and phosphorylates other NHEJ downstream proteins, such as X-ray repair cross-complementing 
protein 4 (XRCC4) and Artemis. DNA ends are subsequently re-ligated by the XRCC4-ligase IV-
XLF complex (Hoeijmakers 2001, Helleday, Petermann et al. 2008) (Fig. 9). 
 
 
 
Fig. 9: Non homologous end joining DNA repair pathway. After the DNA DSBs induced 
by specific nucleases, KU70/80, DNA-PKcs, XRCC4, and Artemis bind at the break site. The 
ends are finally re-ligated by XRCC4-ligase IV-XLF complex, which always results indels.  
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1.3.4 Microhomology-mediated end joining (MMEJ) 
 
In the absence of c-NHEJ factors such as Ku70, Ku80, or DNA ligase IV, yeast and mammalian 
cells are still able to repair DSBs via an alternative form of DSBR, termed microhomology-
mediated end joining (MMEJ) (Deriano and Roth 2013). MMEJ is an error-prone repair 
mechanism that always generates small deletions flanking the DSBs. MMEJ is also associated 
with chromosomal translocations and telomere fusions, thereby resulting in harmful 
consequences on genomic stability (McVey and Lee 2008).  
 
In mammalian cells, both MMEJ and HR share the common initial end resection step mediated 
by MRN complex and CtIP in a CDK-dependent manner, which reveals 5-25 base pair (bp), 
single-strand microhomologous sequences for further sequence alignment (McVey and Lee 2008). 
Repair is completed by annealing of microhomologies, cleavage of 3’ flaps, fill-in DNA synthesis, 
and ligation. Although the MMEJ repair mechanism is still less characterized, numerous studies 
highlight critical roles for XRCC1/DNA ligase III complex, PARP1 and translesion synthesis 
(TLS) DNA polymerase theta (polθ) in regulating MMEJ in higher organisms (Sfeir and 
Symington 2015) (Fig. 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                            1. Introduction 
 
 
 
23 
 
 
 
Fig. 10: Microhomology-mediated end joining DNA repair pathway. In 
the presence of microhomology region in the DNA, the DSBs can also be 
repaired via MMEJ. PARP1, MRE 11 complex, and CtIP plays an important 
role in MMEJ DNA repair. 
 
1.3.5 DNA donor templates 
 
The efficiency of HDR can be influenced by a lot of endogenous and exogenous factors, 
including the cell cycle, the cell type, chromosomal region, the activity of the repair system, and 
the DNA donor template (Yanik, Muller et al. 2016). To enhance HDR, different approaches 
have been developed, including the manipulation of the cell cycle and the regulation of 
expression of key repair pathway proteins (Chu, Weber et al. 2015, Maruyama, Dougan et al. 
2015,Srivastava and Raghavan 2015). However, these invasive manipulations may be undesirable 
for therapeutic applications because they can alter the cellular response to DNA damage at other 
non-target sites in the genome and lead to tumor formation.  
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In contrast, designing optimal DNA donor templates can increase HDR frequencies and at the 
same time leave cell cycle regulation untouched. Linearized or double-stranded DNA plasmid 
sequences, as well as ssDNA oligonucleotides, are used as template for homologous 
recombination at the target site (Fig. 11). Viral vectors such as AAV or IDLV can also be used as 
a source of donor DNA, which provide single-stranded DNA as template for HDR (Hirsch, Green 
et al. 2010, Handel, Gellhaus et al. 2012, Coluccio, Miselli et al. 2013, Genovese, Schiroli et al. 
2014).The size of the intended sequence changes, the length of the homology arms, and the 
insertion site of the mutation are important factors to be considered. Although the exact 
mechanism by which donor design increases HDR frequencies is still under investigation, several 
evidences have shown its influence on gene targeting outcomes. 
 
In mammalian cells, a plasmid donor with at least 1-2 kb of total homology is usually used for 
creating large sequence changes in the presence of target cleavage, including insertion of reporter 
genes such as fluorescent protein or antibiotic resistance markers (Dickinson, Ward et al. 2013, 
Yang, Wang et al. 2013). Without target cleavage, a total of 8-15 kb homology is normally used 
(Wu, Ying et al. 2008). Generally, the efficiency of recombination increases as the length of 
homology arms increases, while the efficiency decreases as the size of the DNA insert increases 
(Li, Wang et al. 2014), but if the homology arms contain repetitive DNA sequences, the targeting 
efficiency will be low (Wu, Ying et al. 2008).  
 
In many proof-of-concept studies, it has been demonstrated that disease-causing mutation can be 
corrected by using DNA donor templates along with targeted nucleases. For the correction of the 
IL2Rγ gene mutation, ca. 1,543 bp centered plasmid donor has been used together with ZFN, 
which has shown about 7% of cells with desired genetic modification (Urnov, Miller et al. 2005).   
 
For small sequence changes, ssDNA sequences are usually more efficient than plasmid donors. 
To correct the duchenne muscular dystrophy gene (Dmd) mutation in the germ line of mdx mice, 
a single-stranded oligodeoxynucleo-tide (ssODN) has been used as a template for HDR-mediated 
gene repair, which contains 90 base pairs (bp) of homology sequence flanking each side of the 
target site (Long, McAnally et al. 2014). Four single stranded Crb1
rd8
 correction ssODNs (200-
                                                                                            1. Introduction 
 
 
 
25 
 
mer and 52-mer, in sense and antisense directions) with homology centered to the targeted region 
has been compared to stimulate HDR events for correction of the Crb1
rd8
 allele in C57BL/6N 
mice, in which 200-mer sense ssODN has shown the best result (Low, Krebs et al. 2014). 
 
Recently, enhanced HDR rates have been reported by using optimized asymmetric ssDNA donor 
templates for conversion of a BFP reporter gene into a GFP reporter gene via mutation of three 
nucleotides within the BFP reading frame (Richardson, Ray et al. 2016). In this study, it has been 
observed that donor DNA complementary to the nontarget strand is more effective than donor 
complementary to the target strand. The optimized donor DNA is complementary to the nontarget 
strand by overlapping the Cas9 cut site with 36 bp in the PAM-distal side, and with 91 bp on the 
PAM-proximal side (Richardson, Ray et al. 2016). It was shown that optimizing a donor template 
at the 5’ and 3’ homology regions flanking the DSB site could boost the frequency of HDR in the 
absence of chemical and genetic intervention. 
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Fig. 11: Design of currently available templates. Templates can be generated as double stranded plasmid, 
linearized plasmid, PCR product, single stranded (ss)DNA or viral vector DNA (AAV or IDLV) (Yanik, 
Muller et al. 2016). 
 
1.3.6 Methods to study DNA repair pathway choices 
 
To quantify the DNA double strand repair outcomes, different methods have been developed 
including PCR amplification, followed by either direct sequencing of the modified region or, if 
the sequence changes containing restriction enzyme recognition sites, restriction-fragment length 
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polymorphism (RFLP) analysis (Ran, Hsu et al. 2013).SURVEYOR nuclease assay is also a 
popular method to quantify the NHEJ events, which is based on the SURVEYOR nuclease 
cleavage of the reannealed heteroduplexes resulted from indels of NHEJ DNA repair (Ran, Hsu 
et al. 2013). In addition, targeted genome modifications can be detected by deep sequencing or 
other next generation sequencing techniques (Ran, Hsu et al. 2013). Several reporter systems 
have also been developed for the direct measurement of the repair events without sequencing, 
including DR-GFP reporter, BFP reporter, and traffic light reporter system (Vriend, Jasin et al. 
2014, Richardson, Ray et al. 2016).  
 
In this work, the traffic light reporter (TLR) system has been used to monitor DNA repair 
activities, which allows rapid observation of repair pathway choices (HR or NHEJ) in cells based 
on fluorescence microscopy and flow-cytometric analysis (FACS).The TLR system consists of a 
non-functional green fluorescent protein (GFP), followed by a self-cleaving T2A peptide and a 
second red fluorescent protein (mCherry) in a reading frame shifted by 2 bp (Certo, Ryu et al. 
2011). The GFP cDNA sequence contains an insertion comprising an I-SceI site and a stop codon, 
which disrupts the normal genetic function. Upon repair of the DSB induced around the stop 
codon, different fluorescent signals will appear depending on whether NHEJ or, in the presence 
of a DNA template, HDR takes place. Mutagenic NHEJ causes insertions and deletions, thus 
shifting the downstream mCherry sequence in frame resulting in a red fluorescent (mCherry) 
signal, whereas homology-directed repair restores the GFP with the help of the DNA donor 
template, resulting in a green fluorescent signal (Certo, Ryu et al. 2011) (Fig. 12). 
 
 
 
 
 
                                                                                            1. Introduction 
 
 
 
28 
 
 
 
Fig. 12: The traffic light reporter system. The TLR system contains a non-functional GFP sequence, and a 
second mCherry sequence in a reading frame shifted by 2 bp. In the GFP cDNA sequence, an I-SceI site and a 
stop codon was inserted resulted in disrupting normal genetic function. Once a DSB is induced around the stop 
codon, it can be repaired through either NHEJ (mCherry) or in the presence of a DNA donor template, HDR 
(GFP) (Certo, Ryu et al. 2011). 
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1.4 Aim 
 
The aim of this work is to optimize DNA double strand break repair induced by specific 
CRISPR-Cas9 nucleases using the Traffic Light Reporter (TLR) system for the development of 
homologous recombination based gene therapy. To improve the HDR rates, double-stranded 
DNA plasmid, linearized plasmid sequence, as well as PCR product will be used as donor 
template with varied homology sequence overlap on the 5’ and 3’ side of the mutation site. 
Furthermore, repair pathway components will be regulated through chemical or genetic 
manipulation to bias repair outcomes toward HDR. 
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2. Material and methods 
 
2.1 Material 
 
2.1.1 Chemicals and reagents 
 
All chemicals and reagents listed in Table 1 were of high purity grade. 
 
Table 1: Chemicals and reagents 
Name Manufacturer 
Accutase PAN 
Agarose seakem LE Biozym 
Ampicillin Sigma-Aldrich 
Boric acid Roth 
Dimethylsulfoxid (DMSO) Sigma-Aldrich 
Disodium phosphate (Na2HPO4) Merck 
Dulbecco's Modified Eagle Medium (DMEM) high glucose PAN 
DNA loading buffer Fermentas 
Ethanol(C2H6O) Roth 
Ethidium bromide (EtBr) Roth 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Fetal bovine serum (FBS) PAN 
GelRed Genaxxon 
Geneticin Life Technologies 
Glycerin(C3H8O3) Merck 
Hydrochloric acid (HCl) Roth 
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Isopropanol (C3H8O) Roth 
Kanamycin Sigma-Aldrich 
L-Glutamine PAN 
Lipofectamine
®
 LTX and PLUS
TM
 Reagents Invitrogen 
Luria broth base Invitrogen 
Monopotassium phosphate (KH2PO4)  Merck 
Penicillin-Streptomycin Biochrom 
Potassium chloride (KCl) Roth 
Select agar Invitrogen 
Sodium chloride (NaCl) Merck 
Sodium hydroxide (NaOH) Roth 
Tris(hydroxymethyl) aminomethane Roth 
 
2.1.2 Buffers 
 
All buffers were prepared with distilled water from the Sartorius water purification system. 
 
Table 2: Buffers 
Name Components 
10x TBE 890 mMTris 
890 mM Boric acid 
20 mM EDTA 
Dissolved in deionized water 
10x PBS 1.37 M NaCl 
27 mMKCl 
100 mM Na2HPO4 
18 mM KH2PO4 
Dissolved in deionized water, PH adjusted to 7.2 with HCl 
Sterilized and autoclaved 
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2.1.3 Media 
 
DMEM (+++) was prepared for eukaryotic cells and LB medium was prepared for prokaryotic 
cells. 
 
Table 3: Media 
Name Components 
DMEM (+++) DMEM 
10% FBS 
2 mM L-glutamine 
50 U/mL Penicillin-Streptomycin 
LB 25 g Luria broth base 
Dissolved in 1 L deionized water  
Autoclaved 
 
 
2.1.4 Plasmids 
 
Table 4: Plasmids and expression vectors 
Name Provider 
pcDNA3.1 (+) Invitrogen 
pcDNA3.1 (-) Invitrogen 
pcDNA5/FRT Invitrogen 
px459 (#48139) Addgene 
hCas9 (#41815) Addgene 
gRNA Cloning Vector (#41824) Addgene 
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2.1.5 Oligonucleotides 
 
Oligonucleotides listed in Table 5 were obtained from Metabion (Planegg-steinkirchen, Germany) 
and used for PCR or Sanger sequencing. 
 
Table 5: Oligonucleotides 
Nr. Name Sequence (5’→3’) 
2493 TLR-2a CGCAAATGGGCGGTAGGCGTGTACG 
2494 TLR-2b TAGAAGGCACAGTCGAGGCTGATCA 
2495 TLR-S1 GAGGGTGGGCCAGGGCACGGGCAGC 
2496 TLR-S2 GACCATGGGCTGGGAGGCCTCCTCC 
2497 TLR-S3 GCAACTACAAGACCCGCGCCGAGGT 
2498 TLR-S4 CTTGTAGGTGGTCTTGACCTCAGCG 
2887 eGFP inf1a GAGGGCGAGGGCGATGCCACCTACGGCAAGCTGAC 
2888 eGFP inf1b GCATCGCCCTCGCCCTCGCCGGACACGCTGAACTT 
2907 delT inf1a TACCCTGTTATCCCTACGCAAAAAGAGCTCACCTACGGC 
2908 delT inf1b GCCGTAGGTGAGCTCTTTTTGCGTAGGGATAACAGGGTA 
2909 delTAinf1a TACCCTGTTATCCCTACGCAAAAGAGCTCACCTACGGC 
2910 delTAinf1b GCCGTAGGTGAGCTCTTTTGCGTAGGGATAACAGGGTA 
2924 dGFP 1a ATGCAGAGGCTCCGGTGCCCGTCAG 
2925 dGFP 1b AGGGCCCGGATTCTCCTCCACGTCA 
2926 dGFP inf1a GAGAATCCGGGCCCTGTGAGCAAGGGCGAGGAGCTGTTCA 
2927 dGFP inf1b CCGGAGCCTCTGCATTTACTTGTACAGCTCGTCCATGCCG 
2928 dGFP S1 AGAACACCCCCATCGGCGACGGCCC 
2933 MY19FS GAGAATCCGGGCCCTAGCGAGCTGATTAAGGAGAACATGC 
2934 MY20FS GAGCCTCTGCATTCAATTAAGCTTGTGCCCCAGTTTGCTA 
2964 Cas Seq1 GTTTTAAAATGGACTATCATATGC 
2965 Cas Seq2 CGCCATCCTGCTGAGCGACATCCTG 
2966 Cas Seq3 GCCATTAAGAAGGGCATCCTGCAG 
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2967 TLR RS55f ACTTGGCAGTACATCTACGTATTAG 
2968 TLR RS55r TTGTCGGGCAGCAGCACGGGGCCG 
2969 TLR RS37f AATGGGCGGTAGGCGTGTACGGTGG 
2970 TLR RS37r CCCTTGCTCACAGGGCCCGGATTC 
2971 TLR RS73f CGTCAATAATGACGTATGTTCCC 
2972 TLR RS73r CTTGAAGTCGATGCCCTTCAGCTCG 
3464 px459 bf GAATTCTAACTAGAGCTCGCTGATC 
3465 px459 br TGGGCCAGGATTCTCCTCGACG 
3466 mRFP f GGAGAATCCTGGCCCAGCCTCCTCCGAGGACGTCATCAAG 
3467 mRFP r CTCTAGTTAGAATTCTTAGGCGCCGGTGGAGTGGCGGCCC 
3242 px459T3f GGTGAGCTCTTATTTGCGTAGTTTTAGAGCTAGAAATAGCAA
G 
3243 px459T3r TACGCAAATAAGAGCTCACCGGTGTTTCGTCCTTTCCACAAG 
3244 px459T4f GGGATAACAGGGTAATGTCGGTTTTAGAGCTAGAAATAGCA
AG 
3245 px459T4r CGACATTACCCTGTTATCCCGGTGTTTCGTCCTTTCCACAAG 
3246 px459T5f GGCCACAAGTTCAGCGTGTCGTTTTAGAGCTAGAAATAGCA
AG 
3247 px459T5r GACACGCTGAACTTGTGGCCGGTGTTTCGTCCTTTCCACAAG 
3305 px459T6f GCCGTCCAGCTCGACCAGGAGTTTTAGAGCTAGAAATAGCA
AG 
3306 px459T6r TCCTGGTCGAGCTGGACGGCGGTGTTTCGTCCTTTCCACAAG 
3307 px459T7f GAGCGCCACCATGGTGAGCAGTTTTAGAGCTAGAAATAGCA
AG 
3308 px459T7r TGCTCACCATGGTGGCGCTCGGTGTTTCGTCCTTTCCACAAG 
3309 px459T8f GGCCGGACACGCTGAACTTGGTTTTAGAGCTAGAAATAGCA
AG 
3310 px459T8r CAAGTTCAGCGTGTCCGGCCGGTGTTTCGTCCTTTCCACAAG 
3238 gRNAT3f TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGG
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TGAGCTCTTATTTGCGTA 
3239 gRNAT3r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTAC
GCAAATAAGAGCTCACC 
3067 gRNAT4f TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGG
GATAACAGGGTAATGTCG 
3068 gRNAT4r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCG
ACATTACCCTGTTATCCC 
3240 gRNAT5f TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGG
CCACAAGTTCAGCGTGTC 
3241 gRNAT5r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGA
CACGCTGAACTTGTGGCC 
3252 gRNAT6f TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGC
CGTCCAGCTCGACCAGGA 
3253 gRNAT6r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTCC
TGGTCGAGCTGGACGGC 
3254 gRNAT7f TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGA
GCGCCACCATGGTGAGCA 
3255 gRNAT7r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACTGC
TCACCATGGTGGCGCTC 
3256 gRNAT8f TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGG
CCGGACACGCTGAACTTG 
3257 gRNAT8r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACCA
AGTTCAGCGTGTCCGGCC 
3298 gesamtTLRf GTTGACATTGATTATTGACTAGT 
3299 gesamtTLRr CAGCTGGTTCTTTCCGCCTCAGAAG 
3329 RS100Af ACTGGACGGCGACGTAAACGGCCAC 
3330 RS100Ar ACGGTGGTGCAGATGAACTTCAGGG 
3417 CasSeqf GAGGGCCTATTTCCCATGATTCC 
3418 CasSeqr GAGAGTGAAGCAGAACGTGGGGC 
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3419 GFPseqf CTCCGCCCCATTGACGCAAATGGG 
3420 GFPseqr GGATGTTGCCGTCCTCCTTGAAGTC 
3191 gRNAseqf GATGCATGCTCGAGCGGCCGCCAG 
3192 gRNAseqr GAGTTAGCTCACTCATTAGGCACC 
 
2.1.6 Enzymes 
 
All the restriction enzymes listed in Table 6 were used with the recommended buffers according 
to the manufacturer’s manual. 
 
Table 6: Restriction enzymes 
Name Manufacturer 
BamHI New England Biolabs (NEB) 
BbsI New England Biolabs (NEB) 
DraIII New England Biolabs (NEB) 
EcoRI New England Biolabs (NEB) 
EcoRV New England Biolabs (NEB) 
HindIII New England Biolabs (NEB) 
NcoI New England Biolabs (NEB) 
NdeI New England Biolabs (NEB) 
NheI New England Biolabs (NEB) 
NotI New England Biolabs (NEB) 
XhoI New England Biolabs (NEB) 
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The polymerases listed in Table 7 were used for PCR reactions. 
 
Table 7: Polymerases 
Name Manufacturer 
PrimeSTAR
®
 HS DNA Polymerase Takara 
Phusion
®
 High-Fidelity DNA Polymerase New England Biolabs (NEB) 
 
2.1.7 Markers 
 
Markers listed in Table 8 were used for DNA gel electrophoresis. 
 
Table 8: Markers 
Name Manufacturer 
GeneRuler 100bp Plus DNA Ladder Fermentas 
GeneRuler 1kb DNA Ladder Fermentas 
 
2.1.8 Kits 
 
All the kits listed in Table 9 were used for DNA purification. 
 
Table 9: DNA purification kits 
Name Manufacturer 
NucleoSpin
®
 Plasmid Macherey-Nagel 
QIAfilter Plasmid Midi Kit Qiagen 
Qiagen Plasmid Maxi Kit Qiagen 
NucleoSpin
®
 Gel and PCR Clean-up Macherey-Nagel 
PureLink
®
 Genomic DNA Mini Kit Invitrogen 
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All the kits listed in Table 10 were used for DNA cloning. 
 
Table 10: DNA cloning kits 
Name Manufacturer 
In-Fusion
®
 HD Cloning Kit Clontech 
TOPO
®
 TA Cloning
®
 Kit Invitrogen 
Zero Blunt
®
 TOPO
®
 PCR Cloning Kit Invitrogen 
 
2.1.9 Bacterial strains 
 
Table 11: Bacterial strains 
Name Manufacturer 
One Shot
®
 TOP10 Chemically Competent E. coli Invitrogen 
One Shot
®
 TOP10 Electrocomp™ E. coli Invitrogen 
Stellar™ Competent Cells Clontech 
 
2.1.10 Devices 
 
Table 12: Devices 
Name Manufacturer 
Incubator Binder 
Autoclave DX-65 Systec GmbH 
Microscopy VWR 
Laminar air flow Invitrogen 
BioDocAnalyze Biometra 
BioPhotometer Eppendorf 
BD Canto II BD 
BD Aria II BD 
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Centrifuge 1-15 PK Sigma 
Centrifuge AK15 Sigma 
CO2 incubator Binder 
Electrophoresis power supply Biometra 
Electrophoresis chambers Biometra 
Fluorescence Microscopy Keyence 
Gel chamber Whatman Biometra 
Thermoblock Biometra 
Vortex VWR 
Ice machine Scotsman 
Magnetic stirrer IKA 
PCR-Cycler T Professional Basic Gradient Biometra 
PH meter Mettler-Toledo GmbH 
Shaker Certomat H Sartorius 
Thermoblock Biometra 
Scale Ohaus 
Water bath TW12 Julabo 
 
 
2.2 Methods 
 
2.2.1 PCR 
 
PCR (Polymerase chain reaction) is a biological molecular method to amplify a particular DNA 
sequence through the thermal cycling. The basic components of the PCR include:  
 
1. DNA template, containing the target DNA region to be amplified;  
2. two primers, complementary to the 3’ ends of the DNA target region; 
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3. DNA polymerase, enabling the amplification;  
4. deoxynucleotide triphosphates (dNTPs), the buliding-blocks of the new synthesized DNA 
strand;  
5. buffer solution, providing a suitable environment for the DNA polymerase and the reaction; 
6. manganese ions, an essential cofactor for the DNA polymerase. 
 
Through a series of repeated temperature changes (cycle), the target region of the DNA template 
can be amplified.  A PCR cycle consists of a denaturation step, an annealing step and an 
elongation step. The denaturation step is preceded by heating the reaction to a temperature of 94-
96 °C which causes DNA melting of the DNA template, yielding single-stranded DNA molecules. 
It is then followed by an annealing step at 50-65 °C which allows the primers annealing to the 
single-stranded DNA template. After the primers anneal to the DNA template, the DNA 
polymerase synthesizes a new DNA strand by adding dNTPs. The new DNA stand is then 
elongated from 5’ to 3’ direction commonly at a temperature of 72 °C. The reaction is finally 
held at 4 °C for a short-term storage. The tables listed below are approach and program for 
Phusion polymerase, which has proof-reading activity. 
 
                         Table 13: PCR approach 
PCR approach for 25 µl 
ddH2O 16.25 µl 
HF Buffer (5x) 5 µl 
dNTP (10 mM) 0.5 µl 
Primer f (10 pmol) 0.5 µl 
Primer r (10 pmol) 0.5 µl 
Phusion Polymerase 0.25 µl 
DNA (100 ng/µl) 2 µl 
Total 25 µl 
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                         Table 14: PCR program 
PCR program 
Cycles Temperature Time 
1 98 °C 30 sec 
 98 °C 10 sec 
35 65 °C 30 sec 
 72 °C 60 sec 
1 72 °C 10 min 
1 10 °C 10 min 
 
 
2.2.2 DNA gel electrophoresis 
 
To analyze the size of the DNA fragments, agarose gel electrophoresis was used. The samples 
were first mixed with 5x loading buffer and loaded on 1% (w/v) agarose gel in 1x TBE buffer 
containing 0.00001% GelRed® (Genaxxon). The run was performed in 1x TBE buffer and the 
bands were visualized and documented using Biodoc Analyze (Biometra). 
 
 
2.2.3 Restriction enzyme digestion 
 
Restriction enzyme digestion has been used to cut the DNA at specific sites. The digestion was 
performed using restriction enzymes purchased from New England Biolabs, according to the 
manufacture’s instruction. The DNA fragments were visualized using gel electrophoresis.  
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2.2.4 Gel extraction 
 
The PCR products were sliced from the agarose gel under UV light with short exposition time 
after gel electrophoresis. They were purified with PCR clean-up Gel extraction kit (Macherey-
Nagel) and finally eluted with ddH2O. The ddH2O was then used as blank value for the 
measurement of the concentration. 
 
2.2.5 Plasmid DNA isolation 
 
Low-scale plasmid DNA was isolated using NucleoSpin
®
 Plasmid QuickPure (Macherey-Nagel) 
kit and high-scale plasmid DNA was isolated using Qiagen
®
 Plasmid Midi or Maxi (Qiagen) kit, 
according to the manufacturer’s instruction. 
 
2.2.6 Genomic DNA isolation 
 
The cells were first harvested in a 50 ml falcon by centrifugation at 1150 rpm (revolutions per 
minute) for 10 min at 4 °C. The supernatant was discarded and the cell pellet was resuspended in 
10 ml 0.15 M KCl. The solution was then centrifuged at 1150 rpm for 10 min at 4 °C. After this 
the supernatant was discarded and the pellet was dissolved in 5 ml SE buffer, 25 µl Proteinase K 
(10 mg/ml) and 250 µl 20% SDS at 55 °C for 3 h. 1.4 ml 6 M NaCl was then added to the cell 
lysis, the solution was vortexed and centrifuged at 5100 rpm for 20 min at 20 °C. The supernatant 
containing the DNA was transferred to a new falcon and 2 Vol ice cold absolute EtOH was added. 
The solution was then inverted and centrifuged at 5100 rpm for 30 min at 4 °C. The DNA pellet 
was then washed with 70% EtOH and dissolved in 100 µl ddH2O. The ddH2O was used as blank 
value for the measurement of the DNA concentration. 
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2.2.7 Transformation 
 
2.2.7.1 Electroporation 
 
Electro-competent cells were first thawed on ice and then gently tapped to ensure that the cells 
were suspended. 2.5 µl plasmid DNA or cloning reaction mixture were added to the cells and 
gently mixed for the evenly distribution.  The tube was leaved on ice for 5-30 min. The mixture 
was then transferred into a cold electroporation cuvette. The transformation was performed in an 
electroporator at 1250 V, 25 mA, and 25 Ω. The cells were resuspended in 1 ml SOC medium 
and transferred into a 1.5 ml tube. The cells were incubated at 37 °C for 60 min while shaking at 
250 rpm. 50 µl of the cells were spread on LB plate containing 100 µg/ml of ampicillin or other 
antibiotic for the cloning vector. 
 
2.2.7.2 Chemical transformation (heat shock) 
 
Chemical-competent cells were first thawed on ice and then gently tapped to ensure that the cells 
were suspended. 2.5 µl plasmid DNA or cloning reaction mixture were added to the cells and 
gently mixed for the evenly distribution.  The tube was leaved on ice for 30 min. The cells were 
heat shocked in a heat block at 42 °C for 45 sec, and then placed directly on ice for 1 min. After a 
heat shock, 450 µl SOC medium was added to the cells. The cells were incubated at 37 °C for 60 
min while shaking at 250 rpm. 50 µl of the cells were spread on LB plate containing 100 µg/ml 
of ampicillin or other antibiotic for the cloning vector.  
 
 
2.2.8 Generation of CRISPR-Cas9 Targets and Cas9-mRFP constructs 
 
The Cas9 expression vector, pSpCas9(BB)-2A-Puro (PX459) V2.0, was purchased from 
Addgene (Cambridge, MA, plasmid 62988). The Cas9 target was cloned into the px459 
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expression vector using In-Fusion Cloning Kit (Clontech, USA), according to the manufacturer’s 
instructions. The puromycin resistance gene was exchanged with mRFP gene using In-Fusion 
Cloning Kit. The plasmid containing mRFR gene was purchased from Addgene (Cambridge, MA, 
plasmid 13032). Plasmids were prepared by using the Qiagen Maxi plasmid kit (Qiagen, 
Germany). 
 
 
2.2.9 Design and generation of donor templates 
 
For the generation of the donor templates, the mutant GFP gene of the TLR3 system was 
corrected with wide type GFP gene sequence by using In-Fusion Cloning Kit (Clontech, USA), 
according to the manufacturer’s instructions. PCR donor templates were amplified using Phusion 
polymerase (NEB, Germany) and the PCR products were further cloned into the TOPO TA 
Cloning Kit (Life Technologies, USA) for the generation of the plasmid donor templates. 
Linearized plasmid donor templates were generated by digesting the plasmids using HindIII and 
DraIII endonuclease (NEB, Germany). The PCR products and linearized plasmid DNA were 
purified using NucleoSpin
®
 Gel and PCR Clean-up Kit (Macherey-Nagel, Germany). Plasmids 
were prepared by using the Qiagen Maxi plasmid kit (Qiagen, Germany). 
 
 
2.2.10 Cell culture and transfection 
 
A stable cell line of HEK293 expressing TLR3 was generated following transfection of a 
pcDNA3.1(-)-TLR3 vector (Life Technologies, Catalog nos. V795-20) and selected using 
neomycin (Life Technologies, Geneticin®, USA). The cell line was maintained in DMEM 
supplemented with 10% FBS, 2 mM L-glutamine, 50 U/mL Penicillin-Streptomycin (Life 
Technologies, USA), and 500 µg/ml Geneticin
®
 and cultured at 37°C with 5% CO2 incubation. 
Transfection of CRISPR-Cas constructs and donor templates was performed using Lipofectamine 
LTX (Life Technologies, USA), with 500 ng plasmid and 500 ng donor templates per well of 24-
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well plate, according to the manufacturer’s instructions. Fluorescence images were visualized 3 
days post-transfection with a Keyence microscope (Keyence, Germany) to control the 
transfection efficacy. 
 
 
2.2.11 Fluorescense-activated cell sorting (FACS) analysis 
 
Cells were collected 3 days after transfection by trypsinization. The supernatant medium was first 
collected in 1.5 ml tube. 200 µl Accutase (PAN-Biotech, Germany)was then added to the cells 
and the cells were incubated at 37°C for 5-10 min. 300 µl DMEM+++ was added to the cells to 
stop the typsinization reaction and the cells was transferred to the tube containing supernatant 
medium. The cells were centrifugated at 300 g for 3 min at 4°C and the cell pellets were washed 
one time with 300 µl PBS. The cells were finally resuspended in 200 µl PBS for FACS analysis. 
FACS analysis of mRFP/BFP/GFP-positive events was performed using BD Canton II flow 
cyctometer (BD Biosciences, Germany). Forward (FSC) versus side (SSC) scatter plots are used 
to select the cells. Typically, 50,000 cells per sample are analyzed. 
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3. Results 
 
3.1 Project strategy 
 
In this study, the traffic light reporter (TLR) system will be used to monitor DNA repair activities, 
which allows rapid observation of repair pathway choices in cells based on fluorescence 
microscopy and flow-cytometric analysis (FACS). The modified TLR system comprises a 
bicistronic expression system of a GFP and a second fluorescent protein BFP. The GFP cDNA 
sequence contains an insertion of a stop codon. Upon repair of the DSB induced close to the stop 
codon, different fluorescent signals will appear depending on whether HDR (green signal) or 
NHEJ (blue signal) takes place.  
 
The site-specific DSBs will be induced by employing the RNA-guided CRISPR-Cas9 system. To 
understand the influence of DNA donor templates on the results of repair pathway choices, 
double-stranded DNA plasmids, linearized plasmids, as well as PCR products will be used and 
the length of the 5’ and 3’ homology arms will be altered. Furthermore, plasmid donors are 
linearized at different sites in the backbone for the generation of differing 5’ and 3’ overhangs to 
investigate whether this also influences HDR activity. To improve the HDR rates, repair pathway 
components will be regulated through chemical or genetic manipulation to bias repair outcomes 
toward HDR (Fig. 13). 
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Fig. 13: Optimizing DNA double strand break repair in modified TLR3 system. Different CRISPR-Cas9 
targets around the stop codon should be designed for the specific cleavage within the GFP sequence in the 
TLR3 system. Depending on the addition of the donor templates, DSBs can be repaired through either NHEJ 
(BFP) or HDR (GFP). To improve the HDR efficiency, different kinds of donor templates should be tested and 
repair key proteins should be regulated. Red line: stop codon. Yellow line: Indels. Black rectangle: mutation 
site. Scissors: site specific CRISPR-Cas9 nucleases. 
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3.2 Establishment of the TLR systems 
 
3.2.1 Generation of the different TLR systems 
 
To enable the observation and analysis under different lasers from fluorescence microscopy and 
flow cytometry, the second fluorescent protein (mCherry) of the TLR1 system was exchanged 
with green fluorescent protein (GFP) (TLR2) and blue fluorescent protein (BFP) (TLR 3) (Fig. 
14).  
 
 
 
TLR1 
 
TLR2 
 
TLR3 
 
 
Fig. 14: TLR1, TLR2, and TLR3 system. The original TLR system (TLR1) consists of a 
mutated GFP sequence, T2A peptide and a second red fluorescent protein (mCherry). The 
second fluorescent gene of modified TLR systems, TLR2 and TLR3, was exchanged with 
GFP and BFP. Red line: stop codon. Black rectangle: mutation site. 
 
 
The original TLR plasmid (TLR1) was purchased from Addgene (Cambridge, MA, plasmid 
#31482) with lentiviral vector backbone. For the in vitro usage in HEK293 cells, the TLR1 
cDNA sequence was cloned into the pcDNA5/FRT, pcDNA3.1(+), or pcDNA3.1(-) vector 
(Thermo Fisher Scientific, USA) under the CMV promoter for high level expression of the gene 
of interest. For the generation of the TLR2 and TLR3 systems, functional GFP and BFP 
sequences were first amplified without ATG start codon and then cloned into the backbone PCR 
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product of TLR1 without mCherry sequence using the In-Fusion Cloning Kit (Clontech, USA) 
(Fig. 15). The plasmids were examined with restriction digestion and Sanger sequencing (Data 
not shown). In this work, TLR3 was used in the cell culture to optimize double strand repair 
pathway choices. 
 
 
 
 
Fig. 15: Cloning strategy of TLR3. pcDNA5/FRT-TLR1 plasmid was first amplified 
without mCherry sequence (PCR primer in pink with arrow). BFP cDNA sequence 
was then amplified without ATG start codon, but with 15 bp extensions homologous 
(PCR primer in blue with arrow and pink overhang) to vector ends. Upon using the In-
Fusion Cloning Kit, the two PCR products are fused due to the 15 bp homology for the 
generation of TLR3 plasmid. Red line: stop codon. Black rectangle: mutation site. 
 
 
3.2.2 Generation of NHEJ and HDR controls for the TLR systems 
 
To establish the TLR systems, artificial NHEJ control (TLR-delTA) was first created through 
deletion of 2 nucleotides (thymin and adenin) of the stop codon within the mutated GFP sequence, 
which removes the stop codon and shifts the second fluorescent gene in frame. In order to create 
the artificial HDR control, the mutated GFP sequence was corrected with the help of wild type 
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GFP sequence for the generation of the functional GFP gene. All the TLR systems, NHEJ 
controls and HDR controls are under the CMV promoter and BGH polyA signal with 
pcDNA5/FRT backbone (Fig. 16). The plasmids were examined through restriction digestion and 
Sanger sequencing (Fig. 17). 
 
 
TLR1-delTA 
 
TLR2-delTA 
 
TLR3-delTA 
 
 
 
TLR1-correctGFP 
 
TLR2-correctGFP 
 
TLR3-correctGFP 
 
 
 
Fig. 16: NHEJ and HDR controls of TLR1, TLR2, and TLR3 system. NHEJ and HDR control for the 
TLR systems were generated through deletion of 2 bp nucleotides (thymine and adenine) and correction of 
mutated GFP sequence, respectively. Grey line: 2 bp deletion. 
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Fig. 17: Comparison of TLR and TLR-delTA sequence. 2 bp of stop codon within 
the mutated GFP sequence were deleted for the generation of the NHEJ control of the 
TLR systems. Black arrow shows the deleted thymine and adenine of the stop codon 
(TAA). The top image shows the Sanger sequencing result of the TLR3 system 
around the stop codon and the bottom image shows the TLR3-delTA control. 
 
 
After the TLR systems and control plasmids were cloned into the pcDNA5/FRT vector, the 
expression of the TLR systems was examined. The transfection efficiency was first optimized 
with different amounts of DNA, different amounts of transfection reagents, and different 
incubation times after the transfection (data not shown). 
 
TLR3 plasmid was transfected into the HEK cells, and observed 72 h after transfection with the 
fluorescence microscope. The transfected cells did not show any fluorescence signal under the 
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BFP and GFP channel, due to the fact that neither the GFP gene nor the BFP gene is expressed 
because of the presence of the stop codon within the mutated GFP sequence. The cells were than 
harvested and analyzed by FACS under BFP and GFP scatter, which shows no detectable GFP 
signal but few BFP positive cells. The appearance of the BFP positive signal is probably because 
of the presence of the intact BFP cDNA sequence, which leads to trans-activation of the second 
BFP gene of the TLR3 system.  
 
TLR3 TLR3-delTA 
  
TLR3-correctGFP TLR1-delTA 
  
 
 
Fig. 18: Microscopy and FACS analysis of TLR control plasmids. TLR3, TLR3-delTA, TLR3-eGFP, 
and TLR1-delTA was transfected into the HEK 293 cells. 72 h after the transfection, the cells were 
observed under the microscopy and analyzed using flow cyctometry. Scale bar: 100 µm.  
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Besides, TLR3-delTA and TLR3-correctGFP plasmids were transfected for the examination of 
the NHEJ and HDR control of the system. Through 2 bp deletion of the TLR3 system, the TLR3-
delTA variant shows the blue fluorescent signal and TLR1-delTA shows red fluorescence signal 
(mCherry). The correction of the mutated GFP sequence leads to the expression of the GFP gene, 
which can be observed by microscope and measured by FACS (Fig. 18). 
 
3.3 Design of different CRISPR-Cas9 targets 
 
3.3.1 Location of six CRISPR-Cas9 targets 
 
To induce the site specific cleavage in the TLR3 system for the stimulation of the DNA repair 
mechanisms, six different target sites were identified upstream or downstream of the stop codon 
within the GFP sequence containing the initiating 5’G and the 3’PAM (NGG), among which T3 
and T4 are inside the mutated GFP sequence. Furthermore, T5 and T7 are located on the 
transcriptionally active strand of the TLR3 cDNA sequence, while T3, T4, T6 and T8 are located 
on the transcriptionally inactive strand of the cDNA sequence (Fig. 19 and Table 15). 
 
Table 15: gRNA sequences targeted TLR3 system 
Name Sequence (GN19NGG) 
T3 GGTGAGCTCTTATTTGCGTAGGG 
T4 GGGATAACAGGGTAATGTCGAGG 
T5 GGCCACAAGTTCAGCGTGTCCGG 
T6 GCCGTCCAGCTCGACCAGGATGG 
T7 GAGCGCCACCATGGTGAGCAAGG 
T8 GGCCGGACACGCTGAACTTGTGG 
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Fig. 19: CRISPR-Cas9 target sites. CRISPR-Cas9 target cleavage sites (T3, T4, T5, T6, T7, 
T8) are around the stop codon in the TLR sequence. 20-nt guide RNA (blue) was designed 
upstream of PAM sequence (NGG; red). Cas9 mediates a DSB 3 bp upstream of the PAM 
sequence. PAM, Proto-Spacer-Adjacent Motif; T, target; Red line: stop codon. 
 
 
3.3.2 Generation of two CRISPR-Cas9 expression systems 
 
In order to study the effect of different gRNA concentrations on cutting efficiency, two CRISPR-
Cas systems were generated, one “all-in-one” vector and one system comprising two plasmids, 
one containing the Cas protein, and one containing the gRNA sequence (Fig. 20). The respective 
guide RNA sequences were cloned into the px459 (Addgene, Cambridge, MA, plasmid #48139) 
expression vector and gRNA cloning vector (Addgene, Cambridge, MA, plasmid #41824). The 
px459 produces the guide RNA and the Cas9 protein simultaneously, while the gRNA cloning 
vector must be coexpressed with an additional hCas9 (Addgene, Cambridge, MA, plasmid 
#41815) expression vector for effective cleavage. Both of the two systems are able to induce 
DNA double strand breaks. 
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Fig. 20: Two CRISPR-Cas9 expression systems. 20 nt guide RNA sequences of the six 
targets were cloned into “All-in-one” vector (px459) and gRNA cloning vector to produce the 
guide RNA and Cas9 protein either simultaneously or separately. 
 
 
3.4 Activity Test of CRISPR-Cas9 targets 
 
After the gRNAs were cloned into the two CRISPR-Cas9 expression systems, the activity of the 
nucleases was tested through cotransfection with the TLR3 plasmid in HEK293 cells. After 72 
hours, the transfected cells were observed under fluorescence microscopy and prepared for FACS 
analysis. By measuring the BFP positive cells, all six targets in both systems showed BFP 
positive signals compared with T0, which indicates that NHEJ takes place (Fig. 21).  
 
While the absolute values varied depending on the transfection efficiency in each experiment, the 
overall outcome that T5 and T7 resulted in highest levels of NHEJ was similar in both CRISPR-
Cas9 expression systems. Interestingly, the latter 4 target sites with lower NHEJ activity are all 
located on the transcriptionally inactive minus strand of the DNA, while the two sites with higher 
activity are located on the transcriptionally active plus strand of the DNA, indicating that NHEJ 
rates are dependent on the location of the target site being on the transcriptionally active or 
inactive DNA strand. 
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Fig. 21: Activity test of both expression systems. CRISPR-Cas9 targets were cotransfected with TLR3 
plasmid in the HEK cells. The BFP positive cells were measured using flow cytometry. px459 T0: empty 
px459 vector. gRNA T0: empty gRNA cloning vector. 
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3.5 Comparison of two CRISPR-Cas9 systems 
 
Upon cotransfection of 800 ng nucleases and 200 ng TLR3 plasmids, the efficacy of the two 
CRISPR-Cas9 expression systems has been compared. With the constant total amount of the 
nucleases, the amount of hCas9 was varied from 0 ng to 800 ng with an increase of 100 ng, while 
the gRNA T5decreased from 800 ng to 0 ng. To compare both Cas9 expression systems, 800 ng 
px459 T5 was cotransfected with 200 ng TLR3 plasmid. 72 hours after transfection, the BFP 
positive cells were first observed under the fluorescence microscope and counted using flow 
cytometry. When looking at the coexpression of hCas9 and gRNA T5, the highest activity has 
been shown by the cotransfection of 200 ng hCas9 and 600 ng gRNA T5, which means 1/3 of 
hCas9 compared to gRNA T5. With the increase of hCas9 amount, the NHEJ activity first 
increased until 200 ng and then decreased dramatically.  Most importantly, px459 T5 has shown 
higher activity than coexpression of hCas9 and gRNA T5 at any concentration. 
 
 
 
Fig. 22: Comparison of two CRISPR-Cas9 systems. Upon cotransfection of 200 ng TLR3 plasmid 
and 800 ng total amounts of nucleases, NHEJ activity was compared. px459 all-in-one vector has 
shown higher activity compared to coexpression of hCas9 and gRNA cloning vector. 
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3.6 Generation of the different donor templates 
 
In order to stimulate HDR events using different kinds of DNA donor templates, 1000 bp DNA 
sequences were generated to correct either centrally (RS55), with a shorter 5’ homologous region 
(RS37), or a shorter 3’ homologous region (RS73). The different lengths of the homologous 
regions are 500 and 500 bp, 300 and 700 bp and vice versa. Four different kinds of DNA were 
employed in the experiments, uncut plasmid, linearized plasmid with 5’ or 3’ backbone overhang, 
or PCR product (Fig. 23). TOPO TA vector backbone has been used for the generation of 
plasmid donor templates, which does not contain eukaryotic promoter. The templates were 
examined using gel electrophoresis (Fig. 24) and Sanger sequencing (Data not shown).  
 
 
 
 
Fig. 23: Generation of different donor templates. a. 1 kb dsDNA donor templates were generated with 
varied homology sequence overlap on the 5’ and 3’ side of the mutation site. b. Donor templates were 
generated as plasmid, linearized plasmid with 5’ or 3’ backbone overhang, or PCR product.  
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Fig. 24: Gel analysis of donor templates. Plasmid DNA containing 1000 bp RS37, 
RS55 and RS73 was linearized with HindIII and DraIII for the generation of the 5’ 
and 3’ backbone overhang. PCR donor templates were amplified using undigested 
Plasmid and Phusion polymerase. 
 
 
3.7 HDR and NHEJ events using uncut plasmid RS55 
 
In order to test HDR frequency in the TLR3 system, the HEK 293 cell line was cotransfected 
with the TLR3, px459 plasmid and the RS55 template plasmid, the latter containing 1000 bp of 
the natural GFP sequence without start region and the sequence to be repaired (i.e. the original 
GFP sequence that had been replaced by the I-SceI site together with the stop codon) located 
centrally. The application of px459 T3 and T4 resulted in a measurable HDR signal, while the 
application of RNA guide T5 did not show any GFP positive signal, indicating the presence of 
DSBs at the target site (Fig. 25). This is due to the fact, that the guide RNA targets a site within 
the natural GFP sequence, representing a reliable control that GFP signaling in our experiments is 
indeed originating from the HDR activity at the target site. 
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Fig. 25: FACS analysis of HDR and NHEJ events using uncut plasmid RS55. TLR3 plasmid was 
cotransfected with nucleases and donor template for the quantification of both HDR and NHEJ events. 
Artificial NHEJ (TLR3-delTA) and HDR (TLR3-correctGFP) control for the TLR systems were generated 
through deletion of 2 bp nucleotides (thymin and adenin) and correction of mutant sequence, respectively. 
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3.8 Creation of TLR3 stable cell line 
 
To quantify the DNA repair outcomes at the genomic level, a stable HEK293-TLR3 cell line was 
created using the linearized pcDNA3.1(-)-TLR3 expression vector, in which the TLR3 system is 
under the control of a CMV promoter. The pcDNA5/FRT-TLR3 was first digested with NheI and 
KpnI and the TLR3 expression cassette was cloned into the pcDNA3.1(-) expression vector. The 
pcDNA3.1(-)-TLR3 was then linearized using PvuI, purified, and transfected into the HEK 293 
cell line (Fig. 26).  
 
 
 
 
Fig. 26: Schematic representation of the generation of HEK 293-TLR3 stable cell line. pcDNA3.1(-)-
TLR3 was first linearized using PvuI, purified, and then transfected into the HEK 293 cell line. 48 h after 
transfection, the positive control of the transfection has been observed. Growth media DMEM has been 
removed and fresh growth media containing Geneticin has been added to the cells for the selection of the 
cells containing gene of interest. After about two weeks, some clones can be observed under the 
microscope; the clones have been picked and transferred into a 24 well with selection media. Genomic 
DNA was isolated from the clone and the expression cassette was amplified using PCR. 
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After 48 hours of transfection, the cells are trypsinized and transferred to a 10 cm plate. Geneticin 
is added to the growth media to select the cells containing TLR3 and maximize the percentage of 
the cell population containing TLR3. Once the cell colonies are formed, they are picked and 
transferred to the 24-well plate. When the cells are 70% confluent in a 24-well plate, they are 
moved to a 6-well plate. Upon having sufficient cells, the cells are harvested and the genomic 
DNA of different colonies is isolated. Total expression cassette of the TLR system is amplified 
using PCR. The PCR products are isolated from the gel and sequenced using Sanger sequencing. 
 
 
 
 
 
Fig. 27: Gel analysis of TLR expression cassette with CMV promoter and BGH polyA signal. Expression 
cassette of the TLR3 system including CMV promoter and BGH polyA was amplified using PCR, the PCR 
product was visualized using gel electrophoresis. The PCR product is 2695 bp. 1-12: clone number. 
 
 
3.9 Activity test of CRISPR-Cas9 targets in HEK-TLR3 stable cell 
line 
 
To examine the efficiency of the six targets (T3-T8) at the genomic level, the respective px459 
vectors were transfected into the HEK293-TLR3 stable cell line and the fluorescing cells were 
counted by FACS. By measuring the BFP positive cells, up to 27% NHEJ events were observed 
using px459-T7, which binds within the 5’ start region of the TLR3 system and T5, which binds 
close to the stop codon. On the other hand, targets T3, T4, T6, and T8 show much lower NHEJ 
rates in the range of 5-7%.  
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Fig. 28: Activity test of px459 CRISPR-Cas targets in HEK-TLR3 stable cell line. 1 µg 
nucleases were transfected into the HEK-TLR3 stable cell line.  72 h after transfection, the 
cells were harvested and BFP positive cells were counted using flow cytometry. 
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Fig. 29: Activity test of gRNA cloning vector and hCas9 expression vector in 
HEK-TLR3 stable cell line. 500 ng gRNA cloning vector and 500 ng hCas9 
expression vector were cotransfected into the HEK-TLR3 stable cell line.  72 h 
after transfection, the cells were harvested and BFP positive cells were counted 
using flow cytometry. 
 
 
3.10 HDR events using different donor templates 
 
Since only T3 or T4 can be used in subsequent experiments and HDR levels for these two sites 
were rather low, the puromycine gene within the px459 plasmid was exchanged by a red 
fluorescent protein (mRFP, px459-mRFP) and cells were sorted prior to the DNA repair activity 
based signaling (blue or green signals) for red fluorescent cells, thus enriching the population of 
successfully transfected cells with the plasmids of interest. 
 
 3. Results 
 
 
 
65 
 
 
 
 
Fig. 30: px459-mRFP variant of CRISPR-Cas9 system. Puromycine gene within the px459 
plasmid has been exchanged by a red fluorescent protein (mRFP) for the enrichment of the 
Cas9 positive cells. 
 
Upon co-transfection of the px459-mRFP vector and the different template versions, FACS based 
quantification of NHEJ and HDR was performed and different template versions compared. Most 
importantly, the use of different donor templates had an effect on the repair outcomes for both, 
HDR and NHEJ, with rates ranging from 0.2% to 2.1%, and 5% to 12%, respectively. 
 
The linearized plasmid with short 5’ backbone overhang (HindIII lin. Pla.) was compared to the 
other three template versions in three different experiments, proving the reproducibility of the 
results (Fig. 31a, c, e). While the absolute values varied depending on the transfection efficiency 
in each experiment, the overall outcome that the RS37 based template resulted in highest levels 
of HDR, followed by RS55, and RS73 revealing the lowest HDR activity, was constantly 
reproducible. In contrast, uncut plasmid DNA template RS55 showed highest HDR activity (Fig. 
31a), and for PCR product and the linearized plasmid with the long 5’ backbone overhang (DraIII 
lin. Pla.) the template version RS73 revealed highest HDR activity (Fig. 31c, e). Notably, 
linearized plasmid with short 5’ backbone overhang and short 5’ homology arm resulted in the 
highest HDR rates observed compared to any other templates (Fig. 31a, c, e).  
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Fig. 31: Optimizing HDR events using different donor templates. Cas9-mRFP targets and donor 
templates were coexpressed in the HEK-TLR3 cell line. 72 h after transfection, flow cytometric 
analysis of mRFP+ gated cells displayed BFP+ (b, d, f, NHEJ repair) cells and GFP+ (a, c, e, HDR 
repair) cells. The graphs represent triplicate data from three independent experiments. T0, px459-
mRFP without guide RNA. RS, repair substrate. Pla, plasmid. lin, linearized. Compared to HindIII 
RS37, significant differences (p˂0.005) have been observed by the template variants HindIII RS73, 
Pla. RS37, Pla. RS73, PCR RS37, PCR RS55, DraIII RS37 and DraIII RS 55.  
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3.11 Inhibition of NHEJ key proteins 
 
Besides the optimization of the donor templates, DNA ligase IV inhibitor Scr7 (purchased from 
Apexbio), and siRNA Ku80 (purchased from Origene) have been used to further optimize the 
HDR rate. Scr7 has been added 4 h after the transfection, while siKu80 has been cotransfected 
with the nucleases and the px459-T3.72 h after transfection, flow cytometric analysis of mRFP+ 
gated cells displayed BFP+ (NHEJ repair) cells and GFP+ (HDR repair) cells. DMSO was used 
as neg. control for the Scr7 inhibitor, in which Scr7 is solved. A universal scrambled siRNA 
control (purchased from Origene) has been used as neg. control for siKu80. A decrease of NHEJ 
signal and increase of HDR signal can be observed after the treatment of Scr7 and siKu80 (Fig. 
32). 
 
  
 
Fig. 32: Optimizing the HDR events using NHEJ key protein inhibitor. 10 mM Scr7 has been added to the 
media 4 h after the transfection and 10 nM siKu80 has been cotransfected with the nuclease px459-T3 and the 
template variant HindIII lin. Pla. RS37. Flow cytometric analysis of mRFP+ gated cells displayed BFP+ (NHEJ 
repair) cells and GFP+ (HDR repair) cells. The graphs represent triplicate data from three independent 
experiments. RS, repair substrate. Pla, plasmid. lin, linearized. Neg, negative. The increases of HDR and 
decreases of NHEJ observed are not significant (p˃0.005). 
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4. Discussion 
 
In therapeutic genome editing applications it is crucial to bias repair outcomes towards high 
fidelity homology directed repair (HDR) and to avoid error prone nonhomologous end-joining 
(NHEJ). In this study, the impact of different repair templates on the frequency of HDR and 
NHEJ was analyzed in a well-defined cell culture system. The study demonstrated that the choice 
of the guide RNA target site has an influence on the activity of DSB repair as measured by NHEJ 
activity and that target sites on the active strand result in higher DSB repair activity compared to 
sites on the inactive DNA strand. More importantly, it was shown that the choice of the template 
DNA has tremendous effects on the outcome of HDR rates, revealing important information for 
the subsequent preparation of genome editing approaches to treat disease-causing mutations.  
 
 
4.1 The traffic light reporter system 
 
Quantitative measurement of both HDR and NHEJ activity is an important aspect of evaluating 
the repair efficiency for further therapeutic genome editing application. The insertions and 
deletions resulting from error prone NHEJ repair are usually small and can range in size from a 
few to tens of nucleotides (Hendel, Fine et al. 2015). To detect these repair outcomes, different 
methods have been developed, such as restriction-fragment length polymorphism (RFLP) assay, 
SURVEYOR assay, Sanger sequencing via cloning of the DNA fragments, next generation 
sequencing (NGS), and some reporter-based quantification methods.  
 
The RFLP assay normally relies on the restriction enzyme digestion of the DNA sequence 
changes after HDR mediated introduction of the specific recognition site, while the SURVEYOR 
assay uses CEL-I nuclease or T7 endonuclease I (T7E1) to digest the mismatch sequence 
resulting from insertions and deletions of NHEJ repair (Pourzand and Cerutti 1993, Qiu, 
Shandilya et al. 2004). Both RFLP and SURVEYOR assays are gel-based mutation detection 
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assays, which are rapid and cost-effective but the sensitivity is relative low. For the comparison 
of HDR activity changes due to different templates used in this study, with differences estimated 
to be below 1%, these methods are not suitable.  
 
Table 16: Comparison of assays for quantifying genome editing outcomes 
Methods to quantify 
repair outcomes 
Quantifi- 
cation of 
HDR 
Quantifi- 
cation of 
NHEJ 
Cost Sensi-
tivity 
Through-
put 
Ref. 
RFLP assay Yes No Low Low Low (Pourzand and 
Cerutti 1993) 
SURVEYOR assay No Yes Low Low Low (Qiu, 
Shandilya et al. 
2004) 
Sanger sequencing 
(Single cell clone 
analysis) 
Yes Yes Low High Low (Ran, Hsu et al. 
2013) 
NGS Yes Yes High High High (Ran, Hsu et al. 
2013) 
DR-GFP reporter 
system 
Yes No Low High High (Pierce, 
Johnson et al. 
1999) 
Integration 
fluorescent gene 
Yes No Low High High (Moehle, Rock 
et al. 2007) 
BFP reporter system Yes Yes Low High High (Richardson, 
Ray et al. 
2016) 
TLR system Yes Yes Low High High (Certo, Ryu et 
al. 2011) 
TLR3 system Yes Yes Low High High This study 
 
 4. Discussion 
 
 
 
70 
 
Targeted genome modifications can also be measured by either Sanger sequencing or next 
generation sequencing (NGS). In Sanger sequencing-based assays, the modified DNA sequences 
are first isolated from the cells and amplified using PCR. The amplicons are subcloned into a 
plasmid vector such as TOPO or pUC19 for transformation, and individual colonies can be 
sequenced by Sanger sequencing for further sequence analysis. Although this sequencing method 
can give more detailed information about the modified events in the genome, the rather small 
number of readouts could be a limiting factor to be considered. Recently, NGS has become a 
popular method to detect repair outcomes. NGS can detect both HDR and NHEJ simultaneously 
with high sensitivity reliably to 0.01% (Hendel, Fine et al. 2015). In contract to Sanger 
sequencing, NGS is more efficient to quantify a large number of samples or target sites with high 
throughput. It should be noted that these sequencing-based assays rely on PCR amplicons and 
large deletions and insertions that span beyond the boundaries of the PCR amplicon are 
potentially less likely amplified and therefore cannot be detected.  
 
Several flow-cytometric based fluorescent reporter systems are also often used to detect the repair 
outcomes. Addition of a fluorescent gene to a defined locus in human cells using donor DNA 
containing locus-specific homology arms and the GFP ORF together with a ZFN demonstrated 
1.4% GFP positive cells, indicating the successful HDR-mediated DNA repair (Moehle, Rock et 
al. 2007). However, this assay cannot quantify the NHEJ repair simultaneously and thus the 
nuclease activity must be quantified using other method. Another approach to estimate the 
efficiency of HR and NHEJ is the BFP reporter system, which is based on the conversion of BFP 
reporter to GFP via a three-nucleotide mutation (Richardson, Ray et al. 2016). It enables a rapid 
observation of both HDR and NHEJ simultaneously. Although this proof-of-concept reporter 
system is highly useful for optimizing DNA repair pathway choices for small sequence changes 
such as SNP mutations, it is not suitable to be used as a model for large sequence changes.  
 
To overcome these limitations, traffic light reporter system (TLR) has been used in this study 
(Certo, Ryu et al. 2011). The traffic light reporter system is able to directly measure the 
efficiency and competition between DNA repair pathway choices at individual DNA breaks. It 
contains a non-functional green fluorescent protein (GFP) gene and a second blue fluorescent 
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protein (BFP) gene in a reading frame shifted by 2 bp. 38 bp sequence changes within the 
mutated GFP sequence is of a comparable size to indel mutations discovered in human genomes 
(Mullaney, Mills et al. 2010). Upon repair of the double-strand break (DSB) close to the stop 
codon within the 38 bp mutated GFP sequence, differing fluorescent signals will appear 
depending on whether homology directed repair (HDR) or non-homologous end-joining (NHEJ) 
takes place. 
 
Of note, BFP signal is generated by +3 frameshifts, but not all indels will shift the reading frame 
into that of BFP, thus +3 frameshifts represents about 1/3 of all the mutagenic events (Certo, Ryu 
et al. 2011). In contrast to BFP signal, GFP signal was generated through the precise repair of the 
GFP cDNA sequence and the normal genetic function is restored by the exogenously provided 
donor template, which shows all HDR events. In this work, all measured cells have been 
represented in the graphic but not the repair events, since the stop codon could be created 
randomly after DSB, and through that a minority -2 frameshifts will not express BFP. Therefore, 
the measured BFP signal is not exact 1/3 of the NHEJ events. However, since we compare data 
from different templates using the same TLR3 system, it does not matter, what the exact number 
of NHEJ events is, but the comparison among the different settings.  
 
An important limitation of this work is the fact that FACS is a cell based detection method. But 
the HEK-TLR3 cell line was generated via random integration resulting in an unknown number 
of copies of the TLR3 reporter sequence in each individual cell. It could be enough to detect the 
fluorescent signal even if one TLR copy is repaired among the unknown copies in the whole 
genome. Nonetheless, to some extent this is a minor consideration for this initial proof-of-concept 
work, since the comparison of the donor templates and the nuclease activity is under the same 
condition. 
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4.2 Cleavage at active or inactive strand 
 
In this study, six different target sites were identified upstream or downstream of the stop codon 
within the mutated GFP sequence of the TLR3 system containing the initiating 5’G and the 
3’PAM (NGG) sequence, among which T3 and T4 cleavage sites are inside the mutated GFP 
sequence. Furthermore, T5 and T7 are located on the transcriptionally activate strand of the 
TLR3 cDNA sequence, while T3, T4, T6 and T8 are located on the transcriptionally inactive 
strand of the cDNA sequence. After the quantification of the BFP (NHEJ) positive cells, all six 
targets showed nuclease activity, among which T5 and T7 resulted in higher NHEJ signals and 
the other 4 target sites resulted in lower NHEJ signals.  
 
Interestingly, the two targets with higher activity are all located on the transcriptionally active 
strand of the DNA, while the four sites with lower activity are located on the transcriptionally 
inactive strand of the DNA, indicating that NHEJ rates are dependent on the location of the target 
site being on the transcriptionally active or inactive DNA strand. Similar results have also been 
observed by Cong and colleagues (Cong, Ran et al. 2013). 16 target sites based on Streptococcus 
pyogenes type II CRISPR and Streptococcus thermophilus CRISPR1 loci have been designed 
against three different genes in human and mouse genomes, most of the targets located on the 
active plus strand have shown higher indel rates than the targets located on the inactive minus 
strand (Cong, Ran et al. 2013).  
 
Recently, the interaction of Cas9 with target DNA has been studied by Richardson and colleagues 
(Richardson, Ray et al. 2016). Understanding the mechanisms of Cas9-DNA interaction could 
suggest strategies to design targets for effective cleavage. They have shown that dissociation of 
Cas9 from double-stranded DNA (dsDNA) substrates is asymmetric and, before complete 
dissociation, Cas9 releases the 3’ end of the PAM distal nontarget strand while holding onto other 
three ends of the target DNA (white crossed circles). Our observation that gRNAs targeting the 
transcriptionally active strand resulted in higher NHEJ signal than gRNAs targeting the 
transcriptionally inactive strand suggests that small indels are more likely to be introduced at the 
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DNA strand that Cas9 releases, and sequence changes on the active plus strand have more 
influence on the NHEJ repair outcome than that on the inactive minus strand. 
 
 
 
Fig. 33: Interaction of Cas9 with target DNA. (A) Cas9 (gray) binds stably to substrate DNA (black). 
RuvC and HNH nuclease domains cut the nontarget and target strands, respectively (red triangles). (B) 
After cleavage, PAM distal non-target strand is released from the Cas9-DNA complex before complete 
dissociation. Modified after (Richardson, Ray et al. 2016). 
 
 
The position of the gRNA target sequence being on the transcriptional active or inactive strand 
has also been analyzed using nicking enzymes and different types of donor template, and the 
authors observed increased DSB repair activity when the site was positioned on the active strand 
(Davis 2014). Although the experimental setups are something different to this study, it suggests 
that designing target sites against the transcriptionally active strand could increase NHEJ activity. 
 
 
4.3 Template DNA 
 
The efficiency of HDR is determined by many factors, of which the donor template is considered 
to be among of the most important ones (Richardson, Ray et al. 2016). Linearized or double-
stranded DNA plasmid sequences, as well as single-stranded DNA oligonucleotides, are often 
used as donor template for large or small sequence changes in the presence of target cleavage 
A                          B 
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(Carroll and Beumer 2014). The length of the homology arm also plays an important role in 
increasing HDR rate since the efficiency of recombination increases as the length of homology 
arms increases (Li, Wang et al. 2014). Here, 1 kb total homology sequence has been chosen for 
the recombination either without CMV promoter sequence or without intact GFP sequence. The 
templates have been generated as double-stranded DNA, PCR product, and linearized plasmid at 
two different backbone sites. 
 
The observation that linearized plasmid is more effective than plasmid donor suggests that 
circular DNAs can be broken randomly at undesired site in the homology arm. In contrast to 
results from the current study in HEK cells, it was observed that plasmid donor is more effective 
than linearized donor in Drosophila embryos probably due to the degradation of the linear DNA 
by exonucleases or conversion of long concatemers (Carroll 2011). The fate of the plasmid donor 
and linearized donor could also be determined by the delivery system since the duration of the 
donor in the cytoplasm increases the degradation rates. 
 
The issue of linearized plasmid vs. PCR product is also an interesting one. Upon generation of 
the plasmid DNA, post-translational modification of the bacteria could be a limiting factor for 
homology directed repair. Another possible reason of the higher HDR efficiency of the linearized 
plasmid is the protection of the backbone sequence from degradation of the template sequence, 
which is not the case for PCR products. 
 
Moreover, the plasmids were linearized at 5’ and 3’ end for the generation of the backbone 
overhang at different sites. Surprisingly, the cut side of the plasmid has resulted indifferent HDR 
and NHEJ rates. It is possible that the overhangs resulted from HindIII and DraIII have different 
affinity to the DNA ends generated from Cas9 protein, so that the random integration of the 
templates into the TLR3 cut site could be different, which in turn influences the NHEJ efficiency. 
Our observation that linearized RS37 showed the best HDR rate suggests that 3’ end degradation 
takes places at the break, while the overhang of the backbone protects the degradation of the 3’ 
end.  
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Furthermore, we have also tried to use ssONGs (100 bp) to stimulate HDR events in our setup, 
but it was not successful, probably due to the large sequence changes (38 bp) inside the TLR3 
system (data not shown). This study showed the importance of choosing the right DNA template 
molecule as one important aspect in the development of future gene therapeutic approaches. 
 
Another key issue in HDR repair is the DNA conversion tract length (DCTL). DCTL shows how 
much donor sequence is transferred to the target and how far synthesis goes during D loop 
formation between the broken DNA and the intact homologous donor sequence. In mammalian 
cells, an early study has examined DCTL in 80 recombinants and has observed relatively short 
DCTL, with 80% of the recombinants having tracts of 58 bp or less (Elliott, Richardson et al. 
1998). A steep decline in the amount of conversion around the double strand break site and up to 
511 bp of gene conversion tracts has been identified in this study. These results suggest that the 
broken ends are protected from extensive degradation prior to or during recombination.  
 
Similar results have been observed in another study, in which DCTL has been tested in 
Drosophila in two different experimental protocols (Beumer, Trautman et al. 2013). After 
induction of ZFN and different donor templates, conversion tracts fell by half about 500 bp on 
either side of the targeted cut site with symmetric distribution and still 50% conversion frequency 
was observed 3 kb or more from the ZFN cut site in the embryo injection protocol. Although the 
tendencies of these two studies are more or less similar, the absolute values of the DCTL are 
totally different, probably due to the different cell types and different length of donor template 
(Fig. 34). Elliott et al has used donor template of 745 bp, while Beumer et al has used 4.2 and 7.5 
kb donor.  
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Fig. 34: DNA conversion tract length during homologous recombination. DCTL is dependent on the 
distance from nuclease cut site and the frequency is dependent on other related factors, such as cell type and 
DNA donor template. The value at the cut site is necessarily 100%. 
 
In this study, CRISPR-Cas9-T3 is directly located within the 38 bp mutated sequence of the 
TLR3 system for the measurement of HDR events, which indicates a higher rate of conversion 
tracts compared to the previous studies although it could not be directly measured. By using other 
targets such as CRISPR-Cas9-T7 with a distance of about 100 bp away from the mutated GFP 
sequence, it is also possible to measure the DCTL in the TLR3 system.  
 
4.4 Approaches to increase HDR 
 
Beside the optimization of the DNA donor templates, several approaches have been developed to 
avoid NHEJ and bias repair towards error free pathways. Regulation of expression of key repair 
pathway proteins, such as inhibiting NHEJ factors by siRNA technology or specific blockers, or 
overexpression of HDR key proteins is another way to enhance HDR (Yanik, Muller et al. 2016). 
Generally, siRNA technology can be applied to all NHEJ proteins such as the KU70/80 complex, 
DNA-PKcs, Artemis and DNA Ligase IV/XRCC4, while inhibitors have been only reported for 
DNA-PKcs and DNA Ligase IV until recently (Srivastava and Raghavan 2015) (Table 17).  
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Table 17: NHEJ inhibitors 
Gene Inhibitor Ref. 
DNA Ligase IV SCR7 
L189 
(Srivastava, Nambiar et al. 2012) 
(Chen, Zhong et al. 2008) 
DNA-PKcs wortmannin 
NU7026 
LY294002 
(Oliveira, Castro et al. 2002) 
(Willmore, de Caux et al. 2004) 
(Rosenzweig, Youmell et al. 1997) 
 
 
DNA-PKcs and KU70/80 complex play an important role in the initial step of NHEJ. Targeting 
proteins involved in the early stage of NHEJ could divert the repair pathway to alternative NHEJ 
or HDR. In contrast, inhibition of the proteins at the final stage of NHEJ, such as DNA LigaseIV 
could lead to accumulation of DNA breaks, which can be lethal to the cells.  However, it has been 
reported that HDR can be significantly increased by using SCR7, a DNA ligase IV inhibitor (Chu, 
Weber et al. 2015, Maruyama, Dougan et al. 2015). Chu et al has reported that the efficiency of 
HDR was increased from 5% to 8-14% in the presence of single shRNAs against KU70, KU80 or 
DNA ligase IV, to 25% by using shRNAs against KU70 and DNA ligase IV or SCR7 (Chu, 
Weber et al. 2015). Up to 19-fold increased HDR efficiency has been observed by Maruyama and 
colleagues by using SCR7 in mammalian cell lines and in mice for four genes (Maruyama, 
Dougan et al. 2015).  
 
Based on these successful previous studies, SCR7 and siRNA against KU80 have been chosen to 
increase HDR in this study. Similar to these two studies, decreased NHEJ activity has been 
observed. Unfortunately, HDR activity did not increased significantly. Compared to the previous 
successful studies, concentration, incubation time, transfection method and cell type could be the 
limiting factors resulting in different outcomes. Further optimization is needed to increase the 
HDR activity.  
 
These approaches, although they seem to be highly useful in some contexts, may be undesirable 
during the in vivo therapeutic application because the molecules are toxic and can alter the 
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cellular response to DNA damage at other non-target sites in the genome and lead to tumor 
formation (Richardson, Ray et al. 2016). Further understanding of the mechanisms and 
optimizing the toxicity are necessary for the clinical application in the future.  
 
 
4.5 Outlook 
 
This study demonstrated the importance of designing CRISPR-Cas9 targets and DNA donor 
templates for the development of HDR mediated therapeutic genome editing approach. The 
limitation of this study is that the off-target toxicity of the CRISPR-Cas9 targets was not analyzed. 
Now, it is of little importance for this proof-of-principle work, but for the long term therapeutic 
application, the off-target analysis needs to be completed. Random integration of introduced 
DNA such as CRISPR-Cas9 expression vector and DNA donor template vector is another issue 
that should be considered.  
 
Once these approaches have been established in the cell culture, they will be applied in vivo in 
the TLR mouse model. The TLR mouse model has been generated by Stieger and colleagues for 
the development of a treatment strategy for X-linked retinitis pigmentosa, of which TLR is 
located adjacent to the mutational hotspot ORF15 of the retinitis pigmentosa GTPase regulator 
(RPGR) gene on the X-chromosome (Stieger, unpublished data). Repair of the TLR system in the 
RPGR gene suggests that the disease-causing mutations in the ORF15 could also be repaired. 
Subsequently, patients suffering from XLRP might be treated by this technique in the long term 
future.
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Summary 
 
The CRISPR-Cas technology enables rapid and precise genome editing at any desired genomic 
position in almost all cells and organisms. For therapeutic application, it is crucial to bias repair 
outcomes towards high fidelity homology directed repair (HDR) and to avoid error prone 
nonhomologous end-joining (NHEJ). In this study, the impact of different repair templates on the 
frequency of homology directed repair (HDR) and non-homologous end-joining (NHEJ) has been 
analyzed.  
 
A stable HEK293 cell line expressing TLR3 was used to quantify HDR and NHEJ events. The 
modified TLR system (TLR3) comprises a bicistronic expression system of a non-functional 
green fluorescent protein (GFP) gene, followed by a self-cleaving T2A peptide and a second blue 
fluorescent protein (BFP) gene in a reading frame shifted by 2 bp. A stable HEK293 cell line 
expressing TLR3 was generated by transfecting a linearized pcDNA3.1(-)-TLR3 plasmid 
followed by neomycin selection. Donor templates of 1000 bp length containing the corrected 
GFP sequence were generated as circular plasmid, linearized plasmid with long 3’ or 5’ backbone 
overhang, or as PCR product. The sequence to be corrected was either centrally located (RS55), 
with a shorter 5’ homologous region (RS37), or a shorter 3’ homologous region (RS73). Six 
different CRISPR-Cas9 target sites were identified upstream or downstream of the stop codon 
within the GFP sequence containing the initiating 5’G and the 3’PAM (NGG).DNA repair 
activity was measured by FACS. 
 
Guide RNAs targeting the active strand (T5, T7) showed higher NHEJ frequencies compared to 
guide RNAs targeting the inactive strand. HDR activity was highest when using the linearized 
plasmid with the short 5’ backbone overhang and the RS37 design, followed by the PCR product 
or the linearized plasmid with the long 5’ backbone overhang, both with RS73 design. Circular 
plasmid was least efficient in generating HDR events.The effect of the different repair templates 
on NHEJ frequencies was marginal. The results demonstrate the importance of the design of the 
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guide RNA and template DNA on the frequency of DNA repair events and thus, ultimately on the 
outcome of treatment approach using HDR. 
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Zusammenfassung 
 
Durch die CRISPR-Cas Technologie ist es möglich, schnelle und genaue Veränderungen in jeder 
gewünschten Gensequenz, in nahezu jedem Zelltyp und Organismus durchzuführen. Wird die 
Technologie zu Therapiezwecken genutzt, ist es wichtig, die Ergebnisse der Reparatur in 
Richtung HDR zu lenken und das fehlerhafte NHEJ zu vermeiden. In dieser Studie wurde der 
Einfluss verschiedener Reparatur-Templates auf die HDR- und NHEJ-Rate analysiert. 
 
Eine stabile HEK293 Zelllinie, die das TLR3 exprimiert, wurde verwendet um die HDR und 
NHEJ Events zu quantifizieren. Das modifizierte TLR System (TLR3) beinhaltet ein 
bicistronisches Expressionssystem. Dieses besteht aus einem nicht funktionellen GFP-Gen 
(grünes Fluoreszenz Protein), gefolgt von einem selbst spaltenden T2A Peptid und einem BFP-
Gen (blaues Fluoreszenz Protein) in einem Leserahmen, der um zwei Basenpaare verschoben ist. 
Eine stabile  HEK293  Zelllinie, die das TLR3 exprimiert, wurde durch Transfektion des 
linearisierten pcDNA3.1(-)-TLR3 Plasmids mit anschließender Neomycin Selektion generiert. 
Die Donor-Templates mit 1000 Basenpaaren Länge, die die korrigierte GFP Sequenz beinhalten, 
wurden in Form des zirkulären Plasmids, des linearisierten Plasmids mit langem 3‘ oder 
5‘ Backbone Überhang, oder des PCR Produkts verwendet. Die zu korrigierende Sequenz liegt 
entweder zentral (RS55), besitzt eine kürzere 5‘ homologe Region (RS37), oder eine kürzere 
3‘ homologe Region (RS73). Sechs verschiedene CRISPR-Cas9 targetsites wurden upstream 
oder downstream des Stopp-Codons  innerhalb der GFP Sequenz, die das initiale  5’G und die 
3‘ PAM (NGG) beinhaltet, identifiziert. Die DNA Reparaturaktivität wurde durch FACS 
gemessen. 
 
Die Guide RNAs, die den aktiven Strang adressieren (T5, T7), zeigen eine höhere NHEJ Rate im 
Vergleich zu den guide RNAs, die den inaktiven Strang adressieren. Die höchste HDR Aktivität 
konnte mit Hilfe des  linearisierten Plasmids mit kurzem 5‘ Backbone Überhang und RS37 
Design erzielt werden, gefolgt von dem PCR Produkt oder dem linearisierten Plasmid mit langem 
5‘ Backbone Überhang, beide mit RS73 Design. Das zirkuläre Plasmid erzeugte am wenigsten 
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HDR Events. Der Effekt der verschiedenen Reparatur-Templates auf die NHEJ Rate ist marginal. 
Die Ergebnisse zeigen den Einfluss des Designs der guide RNA und der Template DNA auf die 
Rate der DNA Reparatur-Events und damit letztlich auf den Erfolg des Therapie-Ansatzes durch 
das Nutzen von HDR. 
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